

LILLY ELI & CO
Form 10-Q
July 30, 2010

Table of Contents

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
Quarterly Report Under Section 13 or 15(d) of the
Securities Exchange Act of 1934
FOR THE QUARTER ENDED JUNE 30, 2010
COMMISSION FILE NUMBER 001-6351
ELI LILLY AND COMPANY
(Exact name of Registrant as specified in its charter)

INDIANA 35-0470950
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
LILLY CORPORATE CENTER, INDIANAPOLIS, INDIANA 46285
(Address of principal executive offices)

Registrant's telephone number, including area code (317) 276-2000

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of a large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

The number of shares of common stock outstanding as of July 20, 2010:

Class	Number of Shares Outstanding
Common	1,153,140,311

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 4. Controls and Procedures

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Item 1a. Risk Factors: Cautionary Statement Regarding Forward Looking Statements

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Item 6. Exhibits

SIGNATURES

INDEX TO EXHIBITS

EX-11

EX-12

EX-31.1

EX-31.2

EX-32

EX-101 INSTANCE DOCUMENT

EX-101 SCHEMA DOCUMENT

EX-101 CALCULATION LINKBASE DOCUMENT

EX-101 LABELS LINKBASE DOCUMENT

EX-101 PRESENTATION LINKBASE DOCUMENT

EX-101 DEFINITION LINKBASE DOCUMENT

Table of Contents**PART I. FINANCIAL INFORMATION***Item 1. Financial Statements*

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

Eli Lilly and Company and Subsidiaries

	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
	(Dollars in millions, except per-share data)			
Revenue	\$ 5,748.7	\$ 5,292.8	\$ 11,234.2	\$ 10,339.8
Cost of sales	1,023.9	947.4	2,146.4	1,763.8
Research and development	1,187.2	1,040.4	2,226.3	1,987.7
Marketing, selling, and administrative	1,755.4	1,708.2	3,369.8	3,237.4
Acquired in-process research and development (Note 3)			50.0	
Asset impairments, restructuring, and other special charges (Note 5)	27.3	105.0	53.5	105.0
Other - net, expense (income) (Note 13)	18.4	24.1	(56.1)	94.8
	4,012.2	3,825.1	7,789.9	7,188.7
Income before income taxes	1,736.5	1,467.7	3,444.3	3,151.1
Income taxes (Note 10)	387.6	309.2	847.3	679.5
Net income	\$ 1,348.9	\$ 1,158.5	\$ 2,597.0	\$ 2,471.6
Earnings per share - basic and diluted (Note 9)	\$ 1.22	\$ 1.06	\$ 2.35	\$ 2.25
Dividends paid per share	\$.49	\$.49	\$.98	\$.98

See Notes to Consolidated Condensed Financial Statements.

Table of Contents

CONSOLIDATED CONDENSED BALANCE SHEETS
Eli Lilly and Company and Subsidiaries

	June 30, 2010	December 31, 2009
	(Dollars in millions)	
	(Unaudited)	
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	\$ 5,163.5	\$ 4,462.9
Short-term investments (Note 6)	33.1	34.7
Accounts receivable, net of allowances of \$105.6 (2010) and \$109.9 (2009)	3,065.2	3,343.3
Other receivables	587.8	488.5
Inventories	2,174.4	2,849.9
Deferred income taxes	314.4	271.0
Prepaid expenses	1,128.0	1,036.2
TOTAL CURRENT ASSETS	12,466.4	12,486.5
OTHER ASSETS		
Investments (Note 6)	1,064.7	1,155.8
Goodwill and other intangibles - net (Note 4)	4,036.0	3,699.8
Sundry	2,371.6	1,921.4
	7,472.3	6,777.0
PROPERTY AND EQUIPMENT		
Land, buildings, equipment, and construction-in-progress	14,044.2	15,100.0
Less accumulated depreciation	(6,259.8)	(6,902.6)
	7,784.4	8,197.4
	\$27,723.1	\$ 27,460.9
LIABILITIES AND SHAREHOLDERS EQUITY		
CURRENT LIABILITIES		
Short-term borrowings	\$ 26.7	\$ 27.4
Accounts payable	950.3	968.1
Employee compensation	585.5	894.2
Sales rebates and discounts	1,288.3	1,109.8
Dividends payable	545.7	538.0
Income taxes payable	435.3	346.7
Other current liabilities	2,492.8	2,683.9
TOTAL CURRENT LIABILITIES	6,324.6	6,568.1
Long-term debt	6,862.2	6,634.7
Accrued retirement benefit (Note 11)	1,882.4	2,334.7

Edgar Filing: LILLY ELI & CO - Form 10-Q

Long-term income taxes payable (Note 10)	1,227.3	1,088.4
Deferred income taxes	80.7	84.8
Other noncurrent liabilities	1,110.6	1,224.9
	11,163.2	11,367.5
SHAREHOLDERS' EQUITY (Notes 7 and 8)		
Common stock	721.3	718.7
Additional paid-in capital	4,668.0	4,635.6
Retained earnings	11,343.7	9,830.4
Employee benefit trust	(3,013.2)	(3,013.2)
Deferred costs-ESOP	(73.3)	(77.4)
Accumulated other comprehensive loss	(3,307.6)	(2,471.9)
Noncontrolling interests	(6.2)	1.6
	10,332.7	9,623.8
Less cost of common stock in treasury	97.4	98.5
	10,235.3	9,525.3
	\$27,723.1	\$ 27,460.9

See Notes to Consolidated Condensed Financial Statements.

Table of Contents

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
Eli Lilly and Company and Subsidiaries

	Six Months Ended June 30,	
	2010	2009
	(Dollars in millions)	
CASH FLOWS FROM OPERATING ACTIVITIES		
Net income	\$ 2,597.0	\$ 2,471.6
Adjustments to reconcile net income to cash flows from operating activities:		
Net marketing investigation charges paid	(80.5)	(1,392.8)
Other changes in operating assets and liabilities	(703.5)	(1,194.9)
Depreciation and amortization	645.0	612.3
Change in deferred income taxes	317.2	340.1
Stock-based compensation expense	128.2	160.4
Acquired in-process research and development, net of tax	32.5	
Other, net	(66.3)	14.5
NET CASH PROVIDED BY OPERATING ACTIVITIES	2,869.6	1,011.2
CASH FLOWS FROM INVESTING ACTIVITIES		
Net purchases of property and equipment	(279.3)	(333.9)
Net change in short-term investments	(2.6)	457.8
Proceeds from sales and maturities of noncurrent investments	383.0	367.4
Purchases of noncurrent investments	(252.2)	(122.8)
Purchase of product rights	(400.0)	
Cash paid for acquisition	(148.4)	
Purchase of in-process research and development	(50.0)	
Other, net	(57.3)	(39.1)
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES	(806.8)	329.4
CASH FLOWS FROM FINANCING ACTIVITIES		
Dividends paid	(1,075.9)	(1,075.8)
Net change in short-term borrowings	(1.3)	(4,812.8)
Proceeds from issuance of long-term debt	0.7	2,400.0
Other, net	(2.0)	(3.4)
NET CASH USED IN FINANCING ACTIVITIES	(1,078.5)	(3,492.0)
Effect of exchange rate changes on cash and cash equivalents	(283.7)	(23.0)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	700.6	(2,174.4)

Edgar Filing: LILLY ELI & CO - Form 10-Q

Cash and cash equivalents at January 1	4,462.9	5,496.7
CASH AND CASH EQUIVALENTS AT June 30	\$ 5,163.5	\$ 3,322.3

See Notes to Consolidated Condensed Financial Statements.

4

Table of Contents

CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
Eli Lilly and Company and Subsidiaries

	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
	(Dollars in millions)			
Net income	\$1,348.9	\$1,158.5	\$2,597.0	\$2,471.6
Other comprehensive (loss) income, net of tax ¹	(530.7)	663.5	(835.7)	320.0
Comprehensive income	\$ 818.2	\$1,822.0	\$1,761.3	\$2,791.6

¹ The significant components of other comprehensive loss were losses from foreign currency translation adjustments of \$543.5 million and \$920.5 million for the three months and six months ended June 30, 2010, respectively. The significant components of other comprehensive income for the three months and six months ended June 30, 2009 were gains from foreign currency translation adjustments of \$596.4 million and

\$192.7 million, respectively. In addition, net unrealized gains on investment securities of \$94.2 million and \$97.0 million were included in other comprehensive income for the three months and six months ended June 30, 2009, respectively.

See Notes to Consolidated Condensed Financial Statements.

5

Table of Contents**SEGMENT INFORMATION**

We operate in one significant business segment - human pharmaceutical products. Operations of the animal health business segment are not material and share many of the same economic and operating characteristics as human pharmaceutical products. Therefore, they are included with pharmaceutical products for purposes of segment reporting. Our business segments are distinguished by the ultimate end user of the product: humans or animals. Performance is evaluated based on profit or loss from operations before income taxes. Income before income taxes for the animal health business for the second quarters of 2010 and 2009 was \$66.4 million and \$47.6 million, respectively, and \$103.1 million and \$83.3 million for the six months ended June 30, 2010 and 2009, respectively.

REVENUE BY CATEGORY

Worldwide revenue by category was as follows:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
	(Dollars in millions)			
Revenue to unaffiliated customers:				
Neuroscience	\$2,363.7	\$2,185.7	\$ 4,607.8	\$ 4,263.4
Endocrinology	1,518.7	1,481.4	2,996.5	2,890.1
Oncology	949.0	838.2	1,856.8	1,635.5
Cardiovascular	532.0	454.1	1,051.7	909.2
Animal health	324.2	275.4	613.8	539.5
Other pharmaceuticals	61.1	58.0	107.6	102.1
Total revenue	\$5,748.7	\$5,292.8	\$11,234.2	\$10,339.8

Table of Contents

NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

Note 1: Basis of Presentation

We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2009. We issued our financial statements by filing with the Securities and Exchange Commission (SEC) and have evaluated subsequent events up to the time of the filing.

Note 2: Implementation of New Financial Accounting Pronouncements

In March 2010, the Financial Accounting Standards Board (FASB) issued an Accounting Standard Update (ASU) related to Revenue Recognition that applies to arrangements with milestones relating to research or development deliverables. This guidance provides criteria that must be met to recognize consideration that is contingent upon achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. This guidance is effective for us January 1, 2011 and is not expected to have a material impact to our consolidated financial position or results of operations.

In 2009, the FASB issued an ASU related to Revenue Recognition that amends the previous guidance on arrangements with multiple deliverables. This guidance provides principles and application guidance on whether multiple deliverables exist, how the arrangements should be separated, and how the consideration should be allocated. It also clarifies the method to allocate revenue in an arrangement using the estimated selling price. This guidance is effective for us January 1, 2011, and is not expected to be material to our consolidated financial position or results of operations.

We adopted the FASB Statement on Transfers and Servicing, an amendment of previous authoritative guidance. The most significant amendments resulting from this Statement consist of the removal of the concept of a qualifying special-purpose entity (SPE) from previous authoritative guidance, and the elimination of the exception for qualifying SPEs from the Consolidation guidance regarding variable interest entities. This Statement was effective for us January 1, 2010, and had no effect on our consolidated financial position or results of operations.

We adopted the FASB Statement that amended the previous Consolidations guidance regarding variable interest entities and addressed the effects of eliminating the qualifying SPE concept from the guidance on Transfers and Servicing. This Statement responded to concerns about the application of certain key provisions of the previous guidance on Consolidations regarding variable interest entities, including concerns over the transparency of enterprises' involvement with variable interest entities. This Statement was effective for us January 1, 2010, and had no effect on our consolidated financial position or results of operations.

Table of Contents

Note 3: Acquisitions

In the second quarter of 2010, we acquired the European marketing rights to several animal health product lines divested by Pfizer Inc. as part of its acquisition of Wyeth, Inc. These products, including vaccines, parasiticides and feed additives, serve both the production animal and companion animal markets. We also acquired a manufacturing facility in Sligo, Ireland, currently used in the production of animal vaccines. This acquisition has been accounted for as a business combination with the purchase price being allocated primarily to product-related intangibles and property and equipment. This acquisition is not material to our consolidated financial statements.

Acquisitions of Marketed Products and Products in Development

In March 2010, we entered into a license agreement with Acrux Limited to acquire the exclusive rights to commercialize its proprietary testosterone solution with the proposed tradename Axiron . The product is currently under regulatory review by the U.S. Food and Drug Administration (FDA) for the treatment of testosterone deficiency in men and has no alternative future use. The charge of \$50.0 million for acquired in-process research and development (IPR&D) related to this arrangement was included as expense in the first quarter of 2010 and is deductible for tax purposes. In connection with this arrangement, our partner is entitled to future milestones and royalties based on sales if this product is approved for commercialization.

Note 4: Collaborations

We often enter into collaborative arrangements to develop and commercialize drug candidates. Collaborative activities might include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These collaborations often require milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the third party. Revenues related to products sold by us pursuant to these arrangements are included in net product sales, while other sources of revenue (e.g., royalties and profit share payments) are included in collaboration and other revenue. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments made to or reimbursements received from our collaboration partners. Each collaboration is unique in nature, and our more significant arrangements are discussed below. The following table summarizes the composition of our total revenue recognized from all transactions, including collaboration activity:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
	(Dollars in millions)			
Net product sales	\$5,589.3	\$5,113.3	\$10,921.8	\$10,005.1
Collaboration and other revenue	159.4	179.5	312.4	334.7
Total revenue	\$5,748.7	\$5,292.8	\$11,234.2	\$10,339.8

Erbitux®

Prior to our acquisition in November 2008, ImClone Systems Inc. (ImClone) entered into several collaborations with respect to Erbitux, a product approved to fight cancer, while still in its development phase. The most significant collaborations operate in these geographic territories: the U.S., Japan, and Canada (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). The agreements are expected to expire in 2018, upon which all

Table of Contents

of the rights with respect to Erbitux in the U.S. and Canada return to us. The following table summarizes the revenue recognized with respect to Erbitux:

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2010	2009	2010	2009
	(Dollars in millions)			
Net product sales	\$ 21.5	\$23.9	\$ 38.4	\$ 50.0
Collaboration and other revenue	82.3	75.8	157.8	143.9
Total revenue	\$103.8	\$99.7	\$196.2	\$193.9

Bristol-Myers Squibb Company

Pursuant to a commercial agreement with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), relating to Erbitux, ImClone is co-developing and co-promoting Erbitux in the U.S. and Canada with BMS, exclusively, and in Japan with BMS and Merck KGaA. The companies have jointly agreed to expand the investment in the ongoing clinical development plan for Erbitux to further explore its use in additional tumor types. Under this arrangement, Erbitux research and development and other costs, up to threshold amounts, are the sole responsibility of BMS, with costs in excess of the thresholds shared by both companies according to a predetermined ratio. Responsibilities associated with clinical and other ongoing studies are apportioned between the parties under the agreement. Collaborative reimbursements received by ImClone for supply of clinical trial materials; for research and development; and for a portion of marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated condensed statement of operations. We receive a distribution fee in the form of a royalty from BMS, based on a percentage of net sales in the U.S. and Canada, which is recorded in collaboration and other revenue. Royalty expense paid to third parties, net of any reimbursements received, is recorded as a reduction of collaboration and other revenue.

We are responsible for the manufacture and supply of all requirements of Erbitux in bulk-form active pharmaceutical ingredient (API) for clinical and commercial use in the territory, and BMS will purchase all of its requirements of API for commercial use from us, subject to certain stipulations per the agreement. Sales of Erbitux to BMS for commercial use are reported in net product sales.

Merck KGaA

A development and license agreement between ImClone and Merck KGaA (Merck) with respect to Erbitux granted Merck exclusive rights to market Erbitux outside of the U.S. and Canada, and co-exclusive rights with BMS and ImClone in Japan. Merck also has rights to manufacture Erbitux for supply in its territory. We manufacture and provide a portion of Merck's requirements for API, which is included in net product sales. We also receive a royalty on the sales of Erbitux outside of the U.S. and Canada, which is included in collaboration and other revenue as earned. Collaborative reimbursements received for supply of product; for research and development; and marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated condensed statement of

Table of Contents

operations. Royalty expense paid to third parties, net of any royalty reimbursements received, is recorded as a reduction of collaboration and other revenue.

Necitumumab

In January 2010, we restructured the commercial agreement with BMS described above to allow for the co-development and co-commercialization of necitumumab, which is currently in Phase III clinical testing for non-small cell lung cancer. Within this restructured arrangement, we and BMS have agreed to share in the cost of developing and potentially commercializing necitumumab in the U.S., Canada, and Japan. We maintain exclusive rights to necitumumab in all other markets. We will fund 45 percent of the development costs for studies that will be used only in the U.S., and 72.5 percent for global studies. We will be responsible for the manufacturing of API, and BMS will be responsible for manufacturing the finished product. We could receive a payment of \$250.0 million upon approval in the U.S. In the U.S. and Canada, BMS will record sales and we will receive 45 percent of the profits for necitumumab, while we will provide 50 percent of the selling effort. In Japan, we and BMS will share costs and profits evenly.

Exenatide

We are in a collaborative arrangement with Amylin Pharmaceuticals (Amylin) for the joint development, marketing, and selling of Byetta® (exenatide injection) and other forms of exenatide such as exenatide once weekly. Byetta is presently approved as an adjunctive therapy to improve glycemic control in patients with type 2 diabetes who have not achieved adequate glycemic control using metformin, a sulfonylurea, or a combination of metformin and sulfonylurea; and in the U.S. only, as an adjunctive therapy in patients using a thiazolidinedione (with or without metformin) and as a monotherapy. Lilly and Amylin are co-promoting exenatide in the U.S. Amylin is responsible for manufacturing and primarily utilizes third-party contract manufacturers to supply Byetta. However, we are manufacturing Byetta pen delivery devices for Amylin. We are responsible for development and commercialization costs outside the U.S. Under the terms of our arrangement, we report as collaboration and other revenue our 50 percent share of gross margin on Amylin's net product sales in the U.S. We report as net product sales 100 percent of sales outside the U.S. and our sales of Byetta pen delivery devices to Amylin. The following table summarizes the revenue recognized with respect to Byetta:

	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
	(Dollars in millions)			
Net product sales	\$ 43.7	\$ 34.7	\$ 87.0	\$ 62.1
Collaboration and other revenue	63.2	79.9	135.7	150.2
Total revenue	\$ 106.9	\$ 114.6	\$ 222.7	\$ 212.3

We pay Amylin a percentage of the gross margin of exenatide sales outside of the U.S., and these costs are recorded in cost of sales. Under the 50/50 profit-sharing arrangement for the U.S., in addition to recording as revenue our 50 percent share of exenatide's gross margin, we also record 50 percent of U.S. research and development costs and marketing and selling costs in the respective line items on the consolidated condensed statements of operations.

A New Drug Application has been submitted to the FDA for Bydureon, the proposed brand name for exenatide once weekly, with the current Prescription Drug User Fee Act action date of October 22, 2010. Amylin is constructing and will operate a manufacturing facility for exenatide once weekly, and we have entered into a supply agreement in which Amylin will supply

Table of Contents

exenatide once weekly product to us for sales outside the U.S. The estimated total cost of the facility is approximately \$550 million. In 2008, we paid \$125.0 million to Amylin, which we will amortize to cost of sales over the estimated life of the supply agreement beginning with product launch. We would be required to reimburse Amylin for a portion of any future impairment of this facility, recognized in accordance with GAAP. A portion of the \$125.0 million payment we made to Amylin would be creditable against any amount we would owe as a result of impairment. We have also agreed to loan up to \$165.0 million to Amylin at an indexed rate, no amounts have been loaned pursuant to this arrangement and any borrowings have to be repaid by June 30, 2014. We have also agreed to cooperate with Amylin in the development, manufacturing, and marketing of exenatide once weekly in a dual-chamber cartridge pen configuration. We will contribute 60 percent of the total initial capital costs of the project, our portion of which will be approximately \$130 million, of which we have contributed approximately \$70 million as of June 30, 2010.

Cymbalta®***Boehringer Ingelheim***

Beginning in 2002, we were in a collaborative arrangement with Boehringer Ingelheim (BI) to jointly develop, market and promote Cymbalta (duloxetine), a product for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and fibromyalgia, outside the U.S. and Japan. Pursuant to the terms of the agreement, we generally shared equally in development, marketing, and selling expenses, and paid BI a commission on sales in the co-promotion territories. We manufacture the product for all territories. Reimbursements or payments for the cost sharing of marketing, selling, and administrative expenses were recorded in the respective expense line items in the consolidated condensed statements of operations. The commission paid to BI was recorded in marketing, selling, and administrative expenses. In March 2010, the parties agreed to terminate this agreement, and the exclusive rights to develop and market duloxetine for all indications in countries outside the U.S. and Japan were re-acquired by us. In connection with the arrangement, we paid BI approximately \$400 million and will also pay to BI a percentage of our sales of duloxetine in these countries through 2012 as consideration for the rights acquired. We record these costs as intangible assets and will amortize to marketing, selling and administrative expenses over the life of the original agreement, which is through 2015.

Quintiles

We were in a collaborative arrangement with Quintiles Transnational Corp. (Quintiles) to jointly market and promote Cymbalta in the U.S. since Cymbalta's launch in 2004. Pursuant to the terms of the agreement, Quintiles shared in the costs to co-promote Cymbalta with us and receives a commission based upon net product sales. According to that agreement, Quintiles' obligation to promote Cymbalta expired during 2009, and we pay a lower rate on net product sales for three years after completion of the promotion efforts specified in that agreement. The commissions paid to Quintiles are recorded in marketing, selling, and administrative expenses.

Effient®

We are in a collaborative arrangement with Daiichi Sankyo Company, Limited (D-S) to develop, market, and promote Effient, an antiplatelet agent for the treatment of patients with acute coronary syndrome (ACS) who are being managed with an artery-opening procedure known as percutaneous coronary intervention (PCI). The product was approved for marketing by the European Commission under the trade name Efiect® in February 2009, and the initial sales were recorded in the first quarter of 2009. The product was also approved for marketing by the FDA under the tradename Effient in July 2009, and the initial sales in the U.S. were recorded in the third quarter of 2009. Within this arrangement, we and D-S have agreed to co-promote under the same trademark in certain territories (including the U.S. and five major European markets), while we have exclusive marketing rights in certain other territories. D-S has exclusive marketing rights in Japan. Under the agreement, we paid D-S an upfront license fee and milestones related to

Table of Contents

successful development and product launch. The parties share approximately 50/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories. We record product sales in our exclusive and co-promotion territories. In our exclusive territories, we pay D-S a royalty specific to these territories. Profit share payments made to D-S are recorded as marketing, selling, and administrative expenses. All royalties paid to D-S and the third-party manufacturer are recorded in cost of sales. Worldwide Effient sales were \$22.9 million and \$31.6 million in the second quarter and first six months of 2010, respectively.

TPG-Axon Capital

In 2008, we entered into an agreement with an affiliate of TPG-Axon Capital (TPG) for the Phase III development of semagacestat and solanezumab, our two lead molecules for the treatment of mild to moderate Alzheimer's disease. Under the agreement, both we and TPG will provide funding for the Alzheimer's clinical trials. Funding from TPG will not exceed \$325.0 million and could extend into 2014. In exchange for their funding, TPG may receive success-based milestones totaling \$330.0 million and mid- to high-single digit royalties that are contingent upon the successful development of the Alzheimer's treatments. The royalties will be paid for approximately eight years after launch of a product. Reimbursements received from TPG for its portion of research and development costs incurred related to the Alzheimer's treatments are recorded as a reduction to the research and development expense line item on the consolidated condensed statements of operations. The reimbursement from TPG has not been and is not expected to be material in any period.

Summary of Collaboration Related Commission and Profit Share Payments

The aggregate amount of commission and profit share payments included in marketing, selling, and administrative expense pursuant to the collaborations described above was \$31.6 million and \$84.6 million in the quarters ended June 30, 2010 and 2009, respectively, and \$96.7 million and \$162.2 million in the six months ended June 30, 2010 and 2009, respectively.

Note 5: Asset Impairments, Restructuring, and Other Special Charges

We recognized asset impairments, restructuring and other special charges of \$27.3 million and \$53.5 million in the second quarter and first six months of 2010, respectively, as a result of our previously announced initiatives to reduce our cost structure and global workforce as well as previously announced strategic decisions. These charges primarily related to severance costs, which are expected to be paid by the end of the third quarter of 2010.

In the second quarter of 2009, we incurred other special charges of \$105.0 million, related to advanced discussions with the attorneys general for several states that were not part of the Eastern District of Pennsylvania settlement, seeking to resolve their Zyprexa[®]-related claims. The charge represented the then-current probable and estimable exposures in connection with the states' claims. Refer to Note 12 for additional information.

Note 6: Financial Instruments

Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-sciences products account for a substantial portion of trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit review procedures and insurance. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate policies, we limit the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management

Table of Contents

instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.

Accounting Policy for Risk-Management Instruments

Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and do not create additional risk because gains and losses on derivative contracts offset losses and gains on the assets, liabilities, and transactions being hedged. As derivative contracts are initiated, we designate the instruments individually as either a fair value hedge or a cash flow hedge. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.

For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized currently in earnings during the period of change.

We may enter into foreign currency forward and purchase option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other-net, expense (income). The purchased option contracts are used to hedge anticipated foreign currency transactions, primarily intercompany inventory activities expected to occur within the next year. These contracts are designated as cash flow hedges of those future transactions, and the impact on earnings is included in cost of sales.

We may enter into foreign currency forward contracts and currency swaps as fair value hedges of firm commitments. Forward and purchase option contracts generally have maturities not exceeding 12 months. At June 30, 2010, we did not hold any foreign currency option contracts. At June 30, 2010, we had outstanding foreign currency forward commitments to purchase 541 million British pounds and sell 652 million euro, commitments to purchase 781 million U.S. dollars and sell 596 million euro, and commitments to buy 933 million euro and sell 1.20 billion U.S. dollars, which will settle within 2 months.

In the normal course of business, our operations are exposed to fluctuations in interest rates. These fluctuations can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest rate exposures, we strive to achieve an acceptable balance between fixed and floating rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt or investments to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating rate debt or investments to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. At June 30, 2010, approximately 94 percent of our total debt is at a fixed rate. We have converted approximately 70 percent of our fixed-rate debt to floating rates through the use of interest rate swaps.

Table of Contents

The Effect of Risk-Management Instruments on the Statement of Operations

The following effects of risk-management instruments were recognized in other-net, expense (income):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2010	2009	2010	2009
	(Dollars in millions)			
Fair value hedges				
Effect from hedged fixed-rate debt	\$ 205.1	\$(179.8)	\$ 236.7	\$(319.4)
Effect from interest rate contracts	(205.1)	179.8	(236.7)	319.4
Cash flow hedges				
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	2.3	2.6	4.5	5.1
Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments	(49.4)	6.8	(46.4)	5.8

The effective portion of net gains on interest rate contracts in designated cash flow hedging relationships recorded in other comprehensive income (loss) was \$0.0 and \$37.8 million for the three months ended June 30, 2010 and June 30, 2009, respectively, and was \$0.0 and \$37.8 million for the six months ended June 30, 2010 and June 30, 2009, respectively.

During the three months and six months ended June 30, 2010 and 2009, net losses related to ineffectiveness and net losses related to the portion of our risk-management hedging instruments, fair value and cash flow hedges excluded from the assessment of effectiveness were not material.

We expect to reclassify \$11.9 million of pretax net losses on cash flow hedges of the variability in expected future interest payments on floating rate debt from accumulated other comprehensive loss to earnings during the next 12 months.

Fair Value of Financial Instruments

The following tables summarize certain fair value information at June 30, 2010 and December 31, 2009 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:

Table of Contents

				Fair Value Measurements Using Quoted Prices in Active Markets	
Diluted	158,925	166,043	158,717	163,835	167,568
See notes to (unaudited) condensed consolidated financial statements.					

3

Table of Contents

STANLEY BLACK & DECKER, INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED BALANCE SHEETS
 SEPTEMBER 28, 2013 AND DECEMBER 29, 2012
 (Unaudited, Millions of Dollars, Except Per Share Amounts)

	September 28, 2013	December 29, 2012
ASSETS		
Current Assets		
Cash and cash equivalents	\$469.1	\$716.0
Accounts and notes receivable, net	1,936.4	1,525.8
Inventories, net	1,629.5	1,304.6
Assets held for sale	15.0	171.7
Other current assets	381.2	393.2
Total Current Assets	4,431.2	4,111.3
Property, Plant and Equipment, net	1,455.4	1,329.9
Goodwill	7,570.7	7,015.5
Intangibles, net	3,118.1	2,931.5
Other Assets	448.3	455.8
Total Assets	\$17,023.7	\$15,844.0
LIABILITIES AND SHAREOWNERS' EQUITY		
Current Liabilities		
Short-term borrowings	\$1,206.5	\$1.1
Current maturities of long-term debt	13.6	10.4
Accounts payable	1,625.9	1,345.9
Accrued expenses	1,097.8	1,680.0
Liabilities held for sale	5.0	37.3
Total Current Liabilities	3,948.8	3,074.7
Long-Term Debt	3,396.9	3,526.5
Deferred Taxes	1,020.2	946.0
Post-retirement Benefits	772.4	816.1
Other Liabilities	867.1	753.6
Commitments and Contingencies (Note R)	—	—
Shareowners' Equity		
Stanley Black & Decker, Inc. Shareowners' Equity		
Preferred stock, without par value:		
Authorized and unissued 10,000,000 shares	—	—
Common stock, par value \$2.50 per share:		
Authorized 300,000,000 shares in 2013 and 2012	442.3	442.3
Issued 176,902,738 shares in 2013 and 2012		
Retained earnings	3,506.0	3,299.5
Additional paid in capital	5,001.9	4,473.5
Accumulated other comprehensive loss	(481.0)	(388.0)
ESOP	(58.6)	(62.8)
	8,410.6	7,764.5
Less: cost of common stock in treasury	(1,473.7)	(1,097.4)
Stanley Black & Decker, Inc. Shareowners' Equity	6,936.9	6,667.1
Non-controlling interests	81.4	60.0
Total Shareowners' Equity	7,018.3	6,727.1

Total Liabilities and Shareowners' Equity	\$17,023.7	\$15,844.0
---	------------	------------

See notes to (unaudited) condensed consolidated financial statements.

4

Table of Contents

STANLEY BLACK & DECKER, INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 THREE AND NINE MONTHS ENDED SEPTEMBER 28, 2013 AND SEPTEMBER 29, 2012
 (Unaudited, Millions of Dollars)

	Third Quarter		Year-to-Date	
	2013	2012	2013	2012
OPERATING ACTIVITIES				
Net earnings attributable to common shareowners	\$166.0	\$115.2	\$434.2	\$391.8
Adjustments to reconcile net earnings to cash provided by operating activities:				
Depreciation and amortization of property, plant and equipment	56.9	53.0	172.4	175.8
Amortization of intangibles	51.9	52.8	150.3	154.8
Loss on debt extinguishment	—	45.5	—	45.5
Pretax gain on sale of business	—	—	(14.0)) —
Asset impairments	18.4	10.8	34.9	10.8
Changes in working capital	(244.2) (174.8) (371.6) (286.0
Changes in other assets and liabilities	50.6	48.7	(269.9) (74.6
Cash provided by operating activities	99.6	151.2	136.3	418.1
INVESTING ACTIVITIES				
Capital expenditures	(94.2) (89.0) (262.1) (259.5
Business acquisitions, net of cash acquired	(16.7) (106.4) (926.6) (695.1
Proceeds from sale of businesses and assets	1.0	2.3	96.5	8.6
Proceeds on net investment hedge settlements	5.3	4.8	7.0	11.8
Cash used in investing activities	(104.6) (188.3) (1,085.2) (934.2
FINANCING ACTIVITIES				
Payments on long-term debt	(0.6) (900.9) (1.7) (1,222.0
Proceeds from long-term borrowings	—	729.4	—	729.4
Stock purchase contract fees	(0.8) (0.8) (2.4) (2.4
Net short-term (repayments) borrowings	(70.9) 527.4	1,199.5	1,316.3
Cash dividends on common stock	(77.5) (82.5) (235.0) (221.3
Premium paid on debt extinguishment	—	(91.0) —	(91.0
Payment on forward stock purchase contract	—	—	(350.0) —
Cash settlement on forward stock purchase contract	18.8	—	18.8	—
Termination of interest rate swaps	—	—	—	35.8
Termination of forward starting interest rate swap	—	—	—	(56.4
Proceeds from issuances of common stock	32.3	27.4	138.7	102.9
Purchases of common stock for treasury	(7.8) —	(32.6) (217.8
Cash (used in) provided by financing activities	(106.5) 209.0	735.3	373.5
Effect of exchange rate changes on cash and cash equivalents	18.9	19.8	(33.3) 5.2
Change in cash and cash equivalents	(92.6) 191.7	(246.9) (137.4
Cash and cash equivalents, beginning of period	561.7	577.8	716.0	906.9
CASH AND CASH EQUIVALENTS, END OF PERIOD	\$469.1	\$769.5	\$469.1	\$769.5

See notes to (unaudited) condensed consolidated financial statements.

Table of Contents

STANLEY BLACK & DECKER, INC. AND SUBSIDIARIES
NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 28, 2013

A. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (hereinafter referred to as "generally accepted accounting principles") for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations for the interim periods have been included and are of a normal, recurring nature. Operating results for the three and nine months ended September 28, 2013 are not necessarily indicative of the results that may be expected for a full fiscal year. For further information, refer to the consolidated financial statements and footnotes included in Stanley Black & Decker, Inc.'s (the "Company") Form 10-K for the year ended December 29, 2012.

In December 2012, the Company sold its Hardware & Home Improvement business ("HHI"), including the residential portion of Tong Lung, to Spectrum Brands Holdings, Inc. ("Spectrum") for approximately \$1.4 billion in cash. The purchase and sale agreement stipulated that the sale occur in a First and Second Closing. The First Closing, which excluded the residential portion of the Tong Lung business, occurred on December 17, 2012 and resulted in an after-tax gain of \$358.9 million. The Second Closing, in which the residential portion of the Tong Lung business was sold for \$93.5 million in cash, occurred on April 8, 2013 and resulted in an after-tax gain of \$4.7 million. The operating results of the residential portion of Tong Lung have been reported as discontinued operations in the Consolidated Statements of Operations and Comprehensive Income through April 8, 2013 as well as the three and nine months ended September 29, 2012, while the operating results of HHI have been reported as discontinued operations for the three and nine months ended September 29, 2012. During the third quarter of 2013, the Company classified two small businesses within the Security and Industrial segments as held for sale based on management's intention to sell these businesses. As a result of this decision, the Company recorded pre-tax impairment losses of \$18.4 million during the third quarter of 2013 in order to remeasure these businesses at estimated fair value less costs to sell. The operating results of these businesses, including the related impairment losses described above, have been reported as discontinued operations for all periods presented. Net sales for discontinued operations totaled \$7.8 million and \$29.0 million for the three and nine months ended September 28, 2013, respectively, and \$268.8 million and \$764.7 million for the three and nine months ended September 29, 2012, respectively. Assets and liabilities held for sale relating to these discontinued operations totaled \$15.0 million and \$5.0 million as of September 28, 2013 and \$171.7 million and \$37.3 million as of December 29, 2012, respectively. For further information regarding the HHI divestiture, refer to the Company's Form 10-K for the year ended December 29, 2012.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements. While management believes that the estimates and assumptions used in the preparation of the financial statements are appropriate, actual results could differ from these estimates.

B. New Accounting Standards

In July 2013, the Financial Accounting Standards Board ("FASB") issued ASU 2013-11 to provide guidance on financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The FASB's objective in issuing this ASU is to eliminate diversity in practice resulting from a lack of guidance on this topic in current U.S. GAAP. New recurring disclosures are not required because the ASU does not affect the recognition or measurement of uncertain tax positions under ASC 740. This ASU is effective for reporting periods beginning after December 15, 2013. Early adoption is permitted. The company did not early adopt this guidance for the period ended September 28, 2013. The company is in the process of quantifying

the effect, if any, of adopting this guidance.

In February 2013, the FASB issued ASU 2013-02, "Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income." This standard requires additional disclosures regarding the reporting of reclassifications out of accumulated other comprehensive income (AOCI). This ASU is effective for reporting periods beginning after December 15, 2012. The Company adopted this guidance during the first quarter of 2013.

In July 2012, the FASB issued ASU 2012-02, "Intangibles - Goodwill and Other (Topic 350)" - Testing Indefinite-Lived Intangibles Assets for Impairment (revised standard). The revised standard is intended to reduce the costs and complexity of the annual impairment testing by providing entities an option to perform a "qualitative" assessment to determine whether further

Table of Contents

impairment testing is necessary. This ASU is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The Company did not early adopt this guidance for its 2012 annual impairment testing. The Company adopted this guidance for its 2013 annual impairment testing performed in the third quarter of 2013.

In December 2011, the FASB issued guidance enhancing disclosure requirements on the nature of an entity's right to offset and related arrangements associated with its financial and derivative instruments. The new guidance requires the disclosure of the gross amounts subject to rights of set-off, amounts offset in accordance with the accounting standards followed, and the related net exposure. The new disclosure requirements are effective for annual reporting periods beginning on or after January 1, 2013 and interim periods therein. The adoption of this guidance did not have a material impact to the Company's consolidated financial statements.

C. Earnings Per Share

The following table reconciles net earnings attributable to common shareowners and the weighted-average shares outstanding used to calculate basic and diluted earnings per share for the three and nine months ended September 28, 2013 and September 29, 2012:

	Third Quarter		Year-to-Date	
	2013	2012	2013	2012
Numerator (in millions):				
Net earnings from continuing operations attributable to common shareowners	\$ 169.9	\$ 90.2	\$ 452.6	\$ 327.5
Net (loss) earnings from discontinued operations	(3.9)	25.0	(18.4)	64.3
Net earnings attributable to common shareowners	\$ 166.0	\$ 115.2	\$ 434.2	\$ 391.8
Less: Earnings attributable to participating restricted stock units ("RSU's")	—	(0.1)	(0.2)	(0.5)
Net Earnings — basic	\$ 166.0	\$ 115.1	\$ 434.0	\$ 391.3
Net Earnings — dilutive	\$ 166.0	\$ 115.2	\$ 434.2	\$ 391.8

	Third Quarter		Year-to-Date	
	2013	2012	2013	2012
Denominator (in thousands):				
Basic earnings per share — weighted-average shares	155,043	162,990	155,140	163,835
Dilutive effect of stock options, awards and convertible preferred units	3,882	3,053	3,577	3,733
Diluted earnings per share — weighted-average shares	158,925	166,043	158,717	167,568
Earnings per share of common stock:				
Basic earnings (loss) per share of common stock:				
Continuing operations	\$ 1.10	\$ 0.55	\$ 2.92	\$ 2.00
Discontinued operations	(0.02)	0.15	(0.12)	0.39
Total basic earnings per share of common stock	\$ 1.07	\$ 0.71	\$ 2.80	\$ 2.39
Diluted earnings (loss) per share of common stock:				
Continuing operations	\$ 1.07	\$ 0.54	\$ 2.85	\$ 1.95
Discontinued operations	(0.02)	0.15	(0.12)	0.38
Total dilutive earnings per share of common stock	\$ 1.04	\$ 0.69	\$ 2.74	\$ 2.34

The following weighted-average stock options and warrants were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive (in thousands):

	Third Quarter		Year-to-Date	
	2013	2012	2013	2012
Number of stock options	—	2,585	569	2,070

Number of stock warrants	—	3,704	—	4,445
--------------------------	---	-------	---	-------

7

Table of Contents

During August and September 2012, 4,938,624 stock warrants expired which were associated with the \$320.0 million convertible notes that matured in May 2012. No shares were issued upon their expiration as the warrants were out of the money.

D. Financing Receivables

Long-term trade financing receivables of \$154.0 million and \$146.0 million at September 28, 2013 and December 29, 2012, respectively, are reported within other assets in the Condensed Consolidated Balance Sheets. Financing receivables and long-term financing receivables are predominately related to certain security equipment leases with commercial businesses. Generally, the Company retains legal title to any equipment leases and bears the right to repossess such equipment in an event of default. All financing receivables are interest bearing and the Company has not classified any financing receivables as held-for-sale. Interest income earned from financing receivables that are not delinquent is recorded on the effective interest method. The Company considers any financing receivable that has not been collected within 90 days of original billing date as past-due or delinquent. Additionally, the Company considers the credit quality of all past-due or delinquent financing receivables as nonperforming.

The Company has an accounts receivable sale program that expires on December 11, 2014. According to the terms of that program the Company is required to sell certain of its trade accounts receivables at fair value to a wholly owned, consolidated, bankruptcy-remote special purpose subsidiary ("BRS"). The BRS, in turn, must sell such receivables to a third-party financial institution ("Purchaser") for cash and a deferred purchase price receivable. The Purchaser's maximum cash investment in the receivables at any time is \$100.0 million. The purpose of the program is to provide liquidity to the Company. The Company accounts for these transfers as sales under Accounting Standards Codification ("ASC") 860, Transfers and Servicing. Receivables are derecognized from the Company's Consolidated Balance Sheet when the BRS sells those receivables to the Purchaser. The Company has no retained interests in the transferred receivables, other than collection and administrative responsibilities and its right to the deferred purchase price receivable. At September 28, 2013, the Company did not record a servicing asset or liability related to its retained responsibility, based on its assessment of the servicing fee, market values for similar transactions and its cost of servicing the receivables sold.

At September 28, 2013 and December 29, 2012, \$75.2 million and \$80.0 million, respectively, of net receivables were derecognized. Gross receivables sold amounted to \$328.9 million (\$286.6 million, net) and \$955.2 million (\$833.9 million, net) for the three and nine months ended September 28, 2013, respectively. These sales resulted in pre-tax loss of \$0.6 million and \$2.1 million for the three and nine months ended September 28, 2013, respectively. Proceeds from transfers of receivables to the Purchaser totaled \$274.2 million and \$781.5 million for the three and nine months ended September 28, 2013, respectively. Collections of previously sold receivables, including deferred purchase price receivables, and all fees, which are settled one month in arrears, resulted in payments to the Purchaser of \$285.4 million and \$786.1 million for the three and nine months ended September 28, 2013, respectively. Servicing fees amounted to \$0.2 million and \$0.4 million for the three and nine months ended September 28, 2013, respectively. Gross receivables sold amounted to \$277.9 million (\$245.2 million, net) and \$844.1 million (\$749.5 million, net) for the three and nine months ended September 29, 2012, respectively. These sales resulted in a pre-tax loss of \$0.8 million and \$2.2 million for the three and nine months ended September 29, 2012, respectively. Proceeds from transfers of receivables to the Purchaser totaled \$241.9 million and \$704.8 million for the three and nine months ended September 29, 2012, respectively. Collections of previously sold receivables, including deferred purchase price receivables, and all fees, which are settled one month in arrears, resulted in payments to the Purchaser of \$251.3 million and \$729.0 million for the three and nine months ended September 29, 2012, respectively. Servicing fees amounted to less than \$0.1 million and \$0.4 million for the three and nine months ended September 29, 2012, respectively.

The Company's risk of loss following the sale of the receivables is limited to the deferred purchase price receivable, which was \$107.1 million at September 28, 2013 and \$45.0 million at December 29, 2012. The deferred purchase price receivable will be repaid in cash as receivables are collected, generally within 30 days, and as such the carrying value of the receivable recorded approximates fair value. There were no delinquencies or credit losses for the three months ended September 28, 2013. Delinquencies and credit losses on receivables sold were \$0.3 million for the nine

months ended September 28, 2013. Delinquencies and credit losses on receivables sold were \$0.4 million and \$0.6 million for the three and nine months ended September 29, 2012. Cash inflows related to the deferred purchase price receivable totaled \$89.6 million and \$257.5 million for the three and nine months ended September 28, 2013, respectively, and \$70.0 million and \$206.6 million for the three and nine months ended September 29, 2012, respectively. All cash flows under the program are reported as a component of changes in accounts receivable within operating activities in the condensed consolidated statements of cash flows since all the cash from the Purchaser is either: 1) received upon the initial sale of the receivable; or 2) from the ultimate collection of the underlying receivables and the underlying receivables are not subject to significant risks, other than credit risk, given their short-term nature.

Table of Contents

E. Inventories

The components of Inventories, net at September 28, 2013 and December 29, 2012 are as follows (in millions):

	2013	2012
Finished products	\$ 1,205.7	\$ 956.8
Work in process	142.1	121.9
Raw materials	281.7	225.9
Total	\$ 1,629.5	\$ 1,304.6

F. Acquisitions

2013 ACQUISITIONS

GQ

On May 28, 2013, the Company purchased a 60% controlling share in Jiangsu Guoqiang Tools Co., Ltd. ("GQ") for a total purchase price of \$48.5 million, net of cash acquired. The fair value of the non-controlling interest is \$34.4 million. GQ is a manufacturer and seller of power tools, armatures and stators in both domestic and foreign markets. The acquisition of GQ complements the Company's existing power tools product offerings and further diversifies the Company's operations and international presence. GQ is headquartered in Qidong, China and is being consolidated into the Company's CDIY segment.

INFASTECH

On February 27, 2013, the Company acquired a 100% ownership interest in Infastech for a total purchase price of \$826.4 million, net of cash acquired. Infastech designs, manufactures and distributes highly-engineered fastening technologies and applications for a diverse blue-chip customer base in the industrial, electronics, automotive, construction and aerospace end markets. The acquisition of Infastech adds to the Company's strong positioning in specialty engineered fastening, an industry with solid growth prospects, and further expands the Company's global footprint with its strong concentration in fast-growing emerging markets. Infastech is headquartered in Hong Kong and is being consolidated into the Company's Industrial segment.

The Infastech acquisition has been accounted for using the acquisition method of accounting which requires, among other things, the assets acquired and liabilities assumed to be recognized at their fair values as of the acquisition date. The following table summarizes the estimated fair values of major assets acquired and liabilities assumed:

(Millions of Dollars)

Cash and cash equivalents	\$82.0
Accounts and notes receivable, net	117.7
Inventories, net	88.4
Prepaid expenses and other current assets	6.2
Property, plant and equipment	48.6
Trade names	22.0
Customer relationships	251.0
Technology	28.0
Other assets	2.4
Accounts payable	(99.2)
Accrued expenses	(36.5)
Deferred taxes	(80.6)
Other liabilities	(6.3)
Total identifiable net assets	\$423.7
Goodwill	484.7

Total consideration transferred

\$908.4

9

Table of Contents

The weighted average useful lives assigned to the trade names, customer relationships, and technology were 15 years, 12.7 years and 10 years, respectively.

Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the expected cost synergies of the combined business, assembled workforce, and the going concern nature of Infastech.

The purchase price allocation for Infastech is preliminary in certain respects. During the measurement period, the Company expects to record adjustments relating to the valuations of certain assets, various opening balance sheet contingencies and income tax matters, amongst others. The Company will complete its purchase price allocation as soon as possible within the measurement period. The finalization of the Company's purchase accounting assessment will result in changes in the valuation of assets acquired and liabilities assumed, which the Company does not expect to be material.

2012 ACQUISITIONS

During 2012, the Company completed seven acquisitions for a total purchase price of \$696.0 million, net of cash acquired. The largest of these acquisitions were AeroScout Inc. ("AeroScout"), which was purchased for \$238.8 million, net of cash acquired, and Powers Fasteners, Inc. ("Powers"), which was purchased for \$220.5 million, net of cash acquired. AeroScout develops, manufactures, and sells Real-Time Locating Systems ("RTLs") primarily to healthcare and certain industrial customers. Powers distributes fastening products such as mechanical anchors, adhesive anchoring systems, and powered forced-entry systems, mainly for commercial construction end customers. AeroScout was purchased in the second quarter of 2012 and has been integrated within the Security and Industrial segments. Powers was also purchased in the second quarter of 2012 and is part of the CDIY segment. The combined assets acquired for these acquisitions, including \$169.9 million of intangible assets and \$7.7 million of cash, was approximately \$279.4 million, and the combined liabilities assumed were approximately \$95.3 million. The related goodwill associated with these two acquisitions is approximately \$282.9 million. The total purchase price for the acquisitions was allocated to the assets acquired and liabilities assumed based on their estimated fair values. The purchase accounting for these acquisitions is complete.

Five smaller acquisitions were completed during 2012 for a total purchase price of 236.7 million. The largest of these acquisitions were Lista North America ("Lista"), which was purchased for \$89.7 million, net of cash acquired, and Tong Lung Metal Industry Co. ("Tong Lung"), which the Company purchased an 89% controlling share for \$102.8 million, net of cash acquired, and assumed \$20.1 million of short term debt. In January 2013, the Company purchased the remaining outstanding shares of Tong Lung for approximately \$12.0 million. Lista's storage and workbench solutions complement the Industrial & Automotive Repair division's tool, storage, radio frequency identification ("RFID") enabled systems, and specialty supply product and service offerings. Tong Lung manufactures and sells commercial and residential locksets. The residential portion of the business was part of the December 2012 HHI sale and closed on April 8, 2013. Lista was purchased in the first quarter of 2012 and is part of the Industrial segment. Tong Lung was purchased in the third quarter of 2012 and is part of the Security segment. The purchase accounting for these acquisitions is complete.

ACTUAL AND PRO-FORMA IMPACT FROM ACQUISITIONS**Actual Impact from Acquisitions**

The following table presents information for Infastech, GQ and other 2013 acquisitions that are included in the Company's Consolidated Statements of Operations and Comprehensive Income:

(Millions of Dollars)	Third Quarter 2013	Year-to-Date 2013
Net Sales	148.6	\$335.1
Net Earnings	8.6	4.7

These amounts include amortization relating to inventory step-up and intangible assets recorded upon acquisition.

Pro-forma Impact from Acquisitions

The following table presents supplemental pro-forma information as if the Infastech, GQ, AeroScout, Powers, and other 2013 and 2012 acquisitions had occurred on January 2, 2012. This pro-forma information includes acquisition-related charges for the period. The pro-forma consolidated results are not necessarily indicative of what the Company's consolidated net earnings would have been had the Company completed these acquisitions on January 2, 2012. In addition, the pro-forma consolidated results do not reflect the expected realization of any cost savings associated with the acquisitions.

Table of Contents

(Millions of Dollars, except per share amounts)	Third Quarter		Year-to-Date	
	2013	2012	2013	2012
Net sales	\$2,761.3	\$2,667.7	\$8,207.2	\$8,027.7
Net earnings attributable to common shareowners	171.0	104.3	483.3	345.7
Diluted earnings per share-continuing operations	1.08	0.63	3.04	2.06

The 2013 pro-forma results were calculated by combining the results of Stanley Black & Decker with the stand-alone results of the 2013 acquisitions for their respective pre-acquisition periods. The following adjustments were made to account for certain costs which would have been incurred during this pre-acquisition period:

Elimination of the historical pre-acquisition intangible asset amortization expense and the addition of intangible asset amortization expense related to intangibles valued as part of the purchase price allocation that would have been incurred from January 1, 2013 to the acquisition dates.

Because the 2013 acquisitions were assumed to occur on January 1, 2012, there were no deal costs or inventory step-up amortization factored into the 2013 pro-forma year, as such expenses would have occurred in the first year following the acquisition.

The 2012 pro-forma results were calculated by combining the results of Stanley Black & Decker with the stand-alone results of the 2012 and 2013 acquisitions for their respective pre-acquisition periods. The following adjustments were made to account for certain costs which would have been incurred during this pre-acquisition period:

Elimination of the historical pre-acquisition intangible asset amortization expense and the addition of intangible asset amortization expense related to intangibles valued as part of the purchase price allocation that would have been incurred from January 2, 2012 to September 29, 2012.

Additional expense for deal costs and inventory step-up, where applicable, which would have been amortized as the corresponding inventory was sold.

Reduced revenue for fair value adjustments made to deferred revenue, where applicable.

Because the 2013 acquisitions were funded using existing sources of liquidity, additional interest expense was factored into the 2012 pro-forma year.

G. Goodwill

Changes in the carrying amount of goodwill by segment are as follows:

(Millions of Dollars)	CDIY	Industrial	Security	Total
Balance December 29, 2012	\$3,030.5	\$1,391.6	\$2,593.4	\$7,015.5
Additions from acquisitions	54.6	513.3	21.6	589.5
Foreign currency translation and other	(21.8) (14.5) 2.0	(34.3
Balance September 28, 2013	\$3,063.3	\$1,890.4	\$2,617.0	\$7,570.7

In accordance with ASC 350, Intangibles - Goodwill and Other, a portion of the goodwill associated with the Security segment was allocated to the residential portion of Tong Lung based on the relative fair value of the business disposed of and the portion of the reporting unit that was retained. Accordingly, in the second quarter of 2013, goodwill for the Security segment was reduced by \$33.6 million and included in the gain on sale of the residential portion of Tong Lung.

Table of Contents

H. Long-Term Debt and Financing Arrangements

Long-term debt and financing arrangements at September 28, 2013 and December 29, 2012 follow:

	Interest Rate	2013	2012
Notes payable due 2016	5.75%	321.7	326.8
Notes payable due in 2018 (junior subordinated)	4.25%	632.5	632.5
Notes payable due 2021	3.40%	388.6	417.1
Notes payable due 2022	2.90%	799.4	799.3
Notes payable due 2028	7.05%	151.8	169.6
Notes payable due 2040	5.20%	330.6	404.4
Notes payable due 2052 (junior subordinated)	5.75%	750.0	750.0
Other, payable in varying amounts through 2021	0.00% – 6.62%	35.9	37.2
Total long-term debt, including current maturities		\$3,410.5	\$3,536.9
Less: Current maturities of long-term debt		(13.6) (10.4
Long-term debt		\$3,396.9	\$3,526.5

At September 28, 2013, the Company's carrying value of the \$300.0 million note payable due in 2016 includes \$13.0 million associated with fair value adjustments made in purchase accounting as well as \$8.7 million pertaining to the unamortized gain on a previously terminated fixed-to-floating interest rate swap.

At September 28, 2013, the Company had a fixed-to-floating interest rate swap on its \$400.0 million notes payable due in 2021. The carrying value of the notes payable due in 2021 includes \$15.0 million pertaining to the unamortized gain on previously terminated swaps offset by \$26.1 million pertaining to fair value adjustments of the active swap and \$0.3 million unamortized discount on the notes.

At September 28, 2013, the Company had a fixed-to-floating interest rate swap on its \$150.0 million notes payable due in 2028. The carrying value of the notes payable due in 2028 includes \$15.6 million associated with fair value adjustments made in purchase accounting partially offset by \$13.8 million pertaining to fair value adjustment of the swap.

At September 28, 2013, the Company had a fixed-to-floating interest rate swap on its \$400.0 million notes payable due in 2040. The carrying value of the notes payable due in 2040 includes a \$69.1 million loss pertaining to the fair value adjustment of the swap and \$0.3 million pertaining to unamortized discount on the notes.

Unamortized gains and fair value adjustments associated with interest rate swaps and the impact of terminated swaps are more fully discussed in Note I, Derivative Financial Instruments.

In June 2013, the Company terminated its four year \$1.2 billion committed credit facility with the concurrent execution of a new five year \$1.5 billion committed credit facility (the "Credit Agreement"). Borrowings under the Credit Agreement may include U.S. Dollars up to the \$1.5 billion commitment or in Euro or Pounds Sterling subject to a foreign currency sub-limit of \$400.0 million and bear interest at a floating rate dependent upon the denomination of the borrowing. Repayments must be made on June 27, 2018 or upon an earlier termination date of the Credit Agreement, at the election of the Company. Simultaneously, the Company terminated its \$1.0 billion 364 day committed credit facility with the concurrent execution of a new \$500 million 364 day committed credit facility (the "Facility"). The Facility contains a one year term-out provision and borrowings under the Facility may include U.S. Dollars up to the \$500 million commitment or in Euro or Pounds Sterling subject to a foreign currency sub-limit of \$250 million and bear interest at a floating rate dependent upon the denomination of the borrowing. Repayments must be made by June 26, 2014, unless the one year term-out election is made, or upon an earlier termination date of the Facility, at the election of the Company. The Credit Agreement and Facility are designated to be a liquidity back-stop for the Company's \$2.0 billion commercial paper program. As of September 28, 2013, the Company has not drawn on either of these commitments.

At September 28, 2013, the Company had \$1.2 billion of borrowings outstanding against the Company's \$2.0 billion commercial paper program. At December 29, 2012, the Company had no commercial paper borrowings outstanding.

Table of Contents

I. Derivative Financial Instruments

The Company is exposed to market risk from changes in foreign currency exchange rates, interest rates, stock prices and commodity prices. As part of the Company's risk management program, a variety of financial instruments such as interest rate swaps, currency swaps, purchased currency options, foreign exchange contracts and commodity contracts may be used to mitigate interest rate exposure, foreign currency exposure and commodity price exposure.

Financial instruments are not utilized for speculative purposes. If the Company elects to do so and if the instrument meets the criteria specified in ASC 815, Derivatives and Hedging, management designates its derivative instruments as cash flow hedges, fair value hedges or net investment hedges. Generally, commodity price exposures are not hedged with derivative financial instruments and instead are actively managed through customer pricing initiatives, procurement-driven cost reduction initiatives and other productivity improvement projects.

A summary of the fair value of the Company's derivatives recorded in the Consolidated Balance Sheets at September 28, 2013 and December 29, 2012 follows (in millions):

	Balance Sheet Classification	2013	2012	Balance Sheet Classification	2013	2012
Derivatives designated as hedging instruments:						
Interest Rate Contracts Fair Value	Other current assets	\$20.3	\$18.5	Accrued expenses	\$1.9	\$3.3
	LT other assets	—	6.4	LT other liabilities	120.7	4.6
Foreign Exchange Contracts Cash Flow	Other current assets	1.6	—	Accrued expenses	1.4	2.6
	LT other assets	0.2	—	LT other liabilities	0.4	—
Net Investment Hedge	Other current assets	1.9	0.2	Accrued expenses	29.5	25.7
		\$24.0	\$25.1		\$153.9	\$36.2
Derivatives not designated as hedging instruments:						
Foreign Exchange Contracts	Other current assets	\$51.6	\$73.9	Accrued expenses	\$14.4	\$46.4
	LT other assets	—	—	LT other liabilities	5.5	8.9
		\$51.6	\$73.9		\$19.9	\$55.3

The counterparties to all of the above mentioned financial instruments are major international financial institutions. The Company is exposed to credit risk for net exchanges under these agreements, but not for the notional amounts. The credit risk is limited to the asset amounts noted above. The Company limits its exposure and concentration of risk by contracting with diverse financial institutions and does not anticipate non-performance by any of its counterparties. Further, as more fully discussed in Note M, Fair Value Measurements, the Company considers non-performance risk of its counterparties at each reporting period and adjusts the carrying value of these assets accordingly. The risk of default is considered remote.

During the nine months ended September 28, 2013 and September 29, 2012, respectively, cash flows related to derivatives including those that are separately discussed in Cash Flow Hedges, Fair Value Hedges and Net Investment Hedges below resulted in net cash received of \$16.7 million and net cash paid of \$29.1 million respectively.

CASH FLOW HEDGES

There was an \$82.6 million and \$93.5 million after-tax mark-to-market loss as of September 28, 2013 and December 29, 2012, respectively, reported for cash flow hedge effectiveness in Accumulated other comprehensive

loss. An after-tax loss of \$11.7 million is expected to be reclassified to earnings as the hedged transactions occur or as amounts are amortized within the next twelve months. The ultimate amount recognized will vary based on fluctuations of the hedged currencies and interest rates through the maturity dates.

Table of Contents

The tables below detail pre-tax amounts reclassified from Accumulated other comprehensive loss into earnings for active derivative financial instruments during the periods in which the underlying hedged transactions affected earnings for the nine months ended September 28, 2013 and September 29, 2012 (in millions):

Year-to-date 2013 (In millions)	Gain (Loss) Recorded in OCI	Classification of Gain (Loss) Reclassified from OCI to Income	Gain (Loss) Reclassified from OCI to Income (Effective Portion)	Gain (Loss) Recognized in Income (Ineffective Portion*)
Foreign Exchange Contracts	\$1.7	Cost of sales	\$ (3.0)	\$ —
Year-to-date 2012 (In millions)	Gain (Loss) Recorded in OCI	Classification of Gain (Loss) Reclassified from OCI to Income	Gain (Loss) Reclassified from OCI to Income (Effective Portion)	Gain (Loss) Recognized in Income (Ineffective Portion*)
Interest Rate Contracts	\$(9.8)	Interest expense	\$ —	\$ —
Foreign Exchange Contracts	\$(11.0)	Cost of sales	\$ 2.2	—

* Includes ineffective portion and amount excluded from effectiveness testing on derivatives.

For the three and nine months ended September 28, 2013, the hedged items' impact to the Consolidated Statements of Operations and Comprehensive Income was a gain of \$0.1 million and \$3.0 million, respectively, in Cost of sales, which is offsetting the loss shown above. For the three and nine months ended September 29, 2012, the hedged items' impact to the Consolidated Statements of Operations and Comprehensive Income was a loss of \$1.2 million and \$2.2 million, respectively, in Cost of sales. There was no impact related to the interest rate contracts' hedged items and the impact of de-designated hedges was immaterial for all periods presented.

For the three and nine months ended September 28, 2013, an after-tax loss of \$2.4 million and \$9.0 million respectively, were reclassified from Accumulated other comprehensive loss into earnings (inclusive of the gain/loss amortization on terminated derivative instruments) during the periods in which the underlying hedged transactions affected earnings. For the three and nine months ended September 29, 2012, an after-tax loss of \$0.1 million and \$0.9 million respectively, were reclassified from Accumulated other comprehensive loss into earnings (inclusive of the gain/loss amortization on terminated derivative instruments) during the periods in which the underlying hedged transactions affected earnings.

Interest Rate Contracts: The Company enters into interest rate swap agreements in order to obtain the lowest cost source of funds within a targeted range of variable to fixed-rate debt proportions. At September 28, 2013, and December 29, 2012, all interest rate swaps designated as cash flow hedges had been terminated.

In December 2009, the Company executed forward starting interest rate swaps with an aggregate notional amount of \$400 million fixing 10 years of interest payments at 4.78%. The objective of the hedge was to offset the expected variability on future payments associated with the interest rate on debt instruments. In January 2012, contracts with a total notional amount of \$240 million of these contracts were terminated. The terminations resulted in cash payments of \$56.4 million, which was recorded in Accumulated other comprehensive loss and will be amortized to earnings over future periods. The cash flows stemming from the termination of such interest rate swaps designated as cash flow hedges are presented within financing activities in the Consolidated Statement of Cash Flows.

Foreign Currency Contracts

Forward Contracts: Through its global businesses, the Company enters into transactions and makes investments denominated in multiple currencies that give rise to foreign currency risk. The Company and its subsidiaries regularly purchase inventory from subsidiaries with non-U.S. dollar functional currencies which creates currency-related volatility in the Company's results of operations. The Company utilizes forward contracts to hedge these forecasted purchases of inventory. Gains and losses reclassified from Accumulated other comprehensive loss for the effective

and ineffective portions of the hedge as well as any amounts excluded from effectiveness testing are recorded in Cost of sales. Gains and losses incurred after a hedge has been de-designated are not recorded in Accumulated other comprehensive income (loss), but are recorded directly to the Consolidated Statements of Operations and Comprehensive Income in Other-net. At September 28, 2013, the notional value of forward currency contracts outstanding was \$146.1 million, all of which was designated, and maturing on various dates through 2014. At December 29, 2012, the notional value of forward currency contracts outstanding was \$154.0 million, all of which was designated, maturing on various dates in 2013.

Table of Contents

Purchased Option Contracts: The Company and its subsidiaries have entered into various inter-company transactions whereby the notional values are denominated in currencies other than the functional currencies of the party executing the trade. In order to better match the cash flows of its inter-company obligations with cash flows from operations, the Company enters into purchased option contracts. Gains and losses reclassified from Accumulated other comprehensive income (loss) for the effective and ineffective portions of the hedge as well as any amounts excluded from effectiveness testing are recorded in Cost of sales. At September 28, 2013, the notional value of purchased option contracts was \$102.0 million maturing on various dates through 2014. As of December 29, 2012, the notional value of purchased option contracts was \$173.0 million, maturing on various dates in 2013.

FAIR VALUE HEDGES

Interest Rate Risk: In an effort to optimize the mix of fixed versus floating rate debt in the Company's capital structure, the Company enters into interest rate swaps. In October 2012, the Company entered into interest rate swaps with notional values which equaled the Company's \$400 million 3.40% notes due in 2021 and the Company's \$400 million 5.20% notes due in 2040. In January 2012, the Company entered into interest rate swaps with notional values which equaled the Company's \$150 million 7.05% notes due in 2028. These interest rate swaps effectively converted the Company's fixed rate debt to floating rate debt based on LIBOR, thereby hedging the fluctuation in fair value resulting from changes in interest rates.

In January 2012, the Company terminated interest rate swaps with notional values equal to the Company's \$300 million 4.75% notes due in 2014, \$300 million 5.75% notes due in 2016, \$200 million 4.90% notes due in 2012 and \$250 million 6.15% notes due in 2013. These terminations resulted in cash receipts of \$35.8 million. The resulting gain of \$28.0 million was deferred and will be amortized to earnings over the remaining life of the notes. In July 2012, the Company repurchased the \$250 million 6.15% notes due in 2013 and \$300 million 4.75% notes due 2014 and, as a result, \$11.1 million of the previously deferred gain was recognized in earnings at that time.

The changes in fair value of the interest rate swaps during the period were recognized in earnings as well as the offsetting changes in fair value of the underlying notes. The notional value of open contracts was \$950 million as of both September 28, 2013 and December 29, 2012. A summary of the fair value adjustments relating to these swaps is as follows (in millions):

	Third Quarter 2013		Year-to-Date 2013	
Income Statement Classification	Gain/(Loss) on Swaps	Gain /(Loss) on Borrowings	Gain/(Loss) on Swaps	Gain /(Loss) on Borrowings
Interest Expense	\$(26.2) \$26.2	\$(118.0) \$118.0
	Third Quarter 2012		Year-to-Date 2012	
Income Statement Classification	Gain/(Loss) on Swaps	Gain /(Loss) on Borrowings	Gain/(Loss) on Swaps	Gain /(Loss) on Borrowings
Interest Expense	\$0.7	\$(0.7) \$25.7	\$(25.7

In addition to the fair value adjustments in the table above, the net swap accruals for each period and amortization of the gains on terminated swaps are also reported as a reduction of interest expense and totaled \$5.7 million and \$17.4 million for the three and nine months ended September 28, 2013, respectively, and \$16.4 million and \$29.6 million for the three and nine months ended September 29, 2012, respectively. Interest expense on the underlying debt was \$11.0 million and \$33.5 million for the three and nine months ended September 28, 2013, respectively, and \$6.0 million and \$21.8 million for the three and nine months ended September 29, 2012, respectively.

NET INVESTMENT HEDGES

Foreign Exchange Contracts: The Company utilizes net investment hedges to offset the translation adjustment arising from re-measurement of its investment in the assets and liabilities of its foreign subsidiaries. The total after-tax amounts in Accumulated other comprehensive income loss were losses of \$60.2 million and \$63.3 million at September 28, 2013 and December 29, 2012, respectively. As of September 28, 2013, the Company had foreign

exchange contracts maturing on various dates through July 2014 with notional values totaling \$966.0 million outstanding hedging a portion of its pound sterling denominated net investment. As of December 29, 2012, the Company had foreign exchange contracts maturing on various dates through October 2013 with notional values totaling \$940.6 million outstanding hedging a portion of its pound sterling denominated net investment. For the nine months ended September 28, 2013, maturing foreign exchange contracts resulted in net cash receipts of \$7.0 million. For the nine months ended September 29, 2012, maturing foreign exchange contracts resulted in net cash receipts of \$11.8 million. Gains and losses on net investment hedges remain in Accumulated other comprehensive income (loss) until disposal of the underlying assets.

Table of Contents

The pre-tax gain or loss from fair value changes was as follows (in millions):

Income Statement Classification	Third Quarter 2013 Amount Recorded in OCI Gain (Loss)	Year-to-Date 2013 Amount Recorded in OCI Gain (Loss)
Other-net	\$(48.4) \$5.1

Income Statement Classification	Third Quarter 2012 Amount Recorded in OCI Gain (Loss)	Year-to-Date 2012 Amount Recorded in OCI Gain (Loss)
Other-net	\$(45.7) \$(52.8)

The effective and ineffective portion (including the ineffective portion and amount excluded from effectiveness testing) recorded in the Income Statements was zero for all periods presented.

UNDESIGNATED HEDGES

Foreign Exchange Contracts: Currency swaps and foreign exchange forward contracts are used to reduce risks arising from the change in fair value of certain foreign currency denominated assets and liabilities (such as affiliate loans, payables and receivables). The objective of these practices is to minimize the impact of foreign currency fluctuations on operating results. The total notional amount of the contracts outstanding at September 28, 2013 was \$2.3 billion of forward contracts and \$104.9 million in currency swaps, maturing on various dates through December 2014. The total notional amount of the contracts outstanding at December 29, 2012 was \$4.3 billion of forward contracts and \$105.6 million in currency swaps, maturing on various dates through December 2014. The income statement impacts related to derivatives not designated as hedging instruments for 2013 and 2012 are as follows (in millions):

Derivatives Not Designated as Hedging Instruments under ASC 815	Income Statement Classification	Third Quarter 2013 Amount of Gain (Loss) Recorded in Income on Derivative	Year-to-Date 2013 Amount of Gain (Loss) Recorded in Income on Derivative
Foreign Exchange Contracts	Other-net	\$ 63.2	\$ 3.0

Derivatives Not Designated as Hedging Instruments under ASC 815	Income Statement Classification	Third Quarter 2012 Amount of Gain (Loss) Recorded in Income on Derivative	Year-to-Date 2012 Amount of Gain (Loss) Recorded in Income on Derivative
Foreign Exchange Contracts	Other-net	\$ 30.3	\$ 30.2

J. Equity Arrangements

In January 2013, the Company elected to prepay the forward share purchase contract on its common stock for \$362.7 million, comprised of the \$350.0 million purchase price, plus an additional amount related to the forward component of the contract. In August 2013, the Company physically settled the contract, receiving 5,581,400 shares and \$18.8 million from the financial institution counterparty representing a purchase price adjustment. The reduction of common shares outstanding was recorded at the inception of the forward share purchase contract and factored into the calculation of weighted average shares outstanding.

In December 2012, the Company entered into a forward starting accelerated share repurchase (“ASR”) contract with certain financial institutions to purchase \$850.0 million of the Company's common stock. The Company paid \$850.0 million to the financial institutions and received an initial delivery of 9,345,794 shares, which reduced the Company's shares outstanding at December 29, 2012. The value of the initial shares received on the date of purchase was \$680.0 million, reflecting a \$72.76 price per share which was recorded as a treasury share purchase for purposes of calculating earnings per share. In accordance with ASC 815-40, the Company recorded the remaining \$170.0 million as a forward contract indexed to its own common stock

Table of Contents

in additional paid in capital. In April 2013, the Company settled the contract and received 1,608,695 shares determined by the average price per share paid by the financial institutions during the purchase period. The average price is calculated using the volume weighted average price ("VWAP") of the Company's stock (inclusive of a VWAP discount) during that period.

In November 2012, the Company purchased from certain financial institutions over the counter "out-of-the-money" capped call options, subject to adjustments for standard anti-dilution provisions, on 10,094,144 shares of its common stock for an aggregate premium of \$29.5 million, or an average of \$2.92 per share. The purpose of the capped call options is to reduce share price volatility on potential future share repurchases. In accordance with ASC 815-40 the premium paid was recorded as a reduction of Shareowners' equity. The average lower strike price is \$71.43 and the average upper strike price is \$79.75, subject to customary market adjustments. The remaining capped call options were net-share settled and the Company received 617,037 shares in April 2013.

Convertible Preferred Units and Equity Option

As described more fully in Note H, Long-Term Debt and Financing Arrangements, of the Company's Form 10-K for the year ended December 29, 2012, in November 2010 the Company issued Convertible Preferred Units comprised of \$632.5 million of Notes due November 17, 2018 and Purchase Contracts. There have been no changes to the terms of the Convertible Preferred Units. The Purchase Contracts obligate the holders to purchase, on the earlier of (i) November 17, 2015 (the Purchase Contract Settlement date) or (ii) the triggered early settlement date, 6,325,000 shares, for \$100 per share, of the Company's 4.75% Series B Cumulative Convertible Preferred Stock (the "Convertible Preferred Stock"), resulting in cash proceeds to the Company of up to \$632.5 million.

Following the issuance of Convertible Preferred Stock upon settlement of a holder's Purchase Contracts, a holder of Convertible Preferred Stock may, at its option, at any time and from time to time, convert some or all of its outstanding shares of Convertible Preferred Stock at a conversion rate of 1.3333 shares of the Company's common stock per share of Convertible Preferred Stock (subject to customary anti-dilution provisions), which is equivalent to an initial conversion price of approximately \$75.00 per share of common stock. Assuming conversion of the 6,325,000 shares of Convertible Preferred Stock at the 1.3333 initial conversion rate, a total of 8,433,123 shares of the Company's common stock may be issued upon conversion. As of September 28, 2013, due to the customary anti-dilution provisions, the conversion rate on the Convertible Preferred Stock is 1.3552 (equivalent to a conversion price of approximately \$73.79 per common share). In the event that holders elect to settle their Purchase Contracts prior to November 17, 2015, the Company will deliver a number of shares of Convertible Preferred Stock equal to 85% of the Purchase Contracts tendered, together with cash in lieu of fractional shares. Upon a conversion on or after November 15, 2015 the Company may elect to pay or deliver, as the case may be, solely shares of common stock, together with cash in lieu of fractional shares ("physical settlement"), solely cash ("cash settlement"), or a combination of cash and common stock ("combination settlement"). The Company may redeem some or all of the Convertible Preferred Stock on or after December 22, 2015 at a redemption price equal to 100% of the \$100 liquidation preference per share plus accrued and unpaid dividends to the redemption date.

In November 2010, contemporaneously with the issuance of the Convertible Preferred Units described above, the Company paid \$50.3 million, or an average of \$5.97 per option, to enter into capped call transactions (equity options) on 8,433,123 shares of common stock with certain major financial institutions. The purpose of the capped call transactions is to offset the common shares that may be deliverable upon conversion of shares of Convertible Preferred Stock. With respect to the impact on the Company, the capped call transactions and the Convertible Preferred Stock, when taken together, result in the economic equivalent of having the conversion price on the Convertible Preferred Stock at \$96.37, the upper strike price of the capped call (as of September 28, 2013). Refer to Note H, Long-Term Debt and Financing Arrangements, and Note J, Capital Stock, of the Company's Form 10-K for the year ended December 29, 2012 for further discussion. In accordance with ASC 815-40 the \$50.3 million premium paid was recorded as a reduction to equity.

The capped call transactions cover, subject to customary anti-dilution adjustments, the number of shares of common stock equal to the number of shares of common stock underlying the maximum number of shares of Convertible Preferred Stock issuable upon settlement of the Purchase Contracts. Each of the capped call transactions has a term of

approximately 5 years and initially had a lower strike price of \$75.00, which corresponded to the initial conversion price of the Convertible Preferred Stock, and an upper strike price of \$97.95, which was approximately 60% higher than the closing price of the common stock on November 1, 2010. The capped call transactions may be settled by net share settlement (the default settlement method) or, at the Company's option and subject to certain conditions, cash settlement, physical settlement or modified physical settlement. The aggregate fair value of the options at September 28, 2013 was \$106.1 million.

Table of Contents

K. Accumulated Other Comprehensive Income (Loss)

The table below sets forth the changes to the components of accumulated other comprehensive income (loss) for the nine months ended September 28, 2013 (in millions):

	Currency translation adjustment	Unrealized (losses) gains on cash flow hedges, net of tax	Unrealized (losses) gains on net investment hedges, net of tax	Pension (losses) gains, net of tax	Total
Balance - December 29, 2012	\$29.4	\$(93.5)	\$(63.3)	\$(260.6)	\$(388.0)
Other comprehensive (loss) income before reclassifications	\$(111.2)	\$1.9	\$3.1	\$(1.2)	\$(107.4)
Reclassification adjustments to earnings	—	9.0	—	5.4	14.4
Net other comprehensive (loss) income	\$(111.2)	\$10.9	\$3.1	\$4.2	\$(93.0)
Balance - September 28, 2013	\$(81.8)	\$(82.6)	\$(60.2)	\$(256.4)	\$(481.0)

The reclassifications out of accumulated other comprehensive income (loss) for the nine months ended September 28, 2013 were as follows (in millions):

Reclassifications from accumulated other comprehensive income (loss) to earnings	Reclassification adjustments	Affected line item in Consolidated Statements of Operations And Comprehensive Income
Realized losses on cash flow hedges	\$(14.3)	Cost of sales
Tax effect	5.3	Income taxes on continuing operations
Realized losses on cash flow hedges, net of tax	\$(9.0)	
Amortization of defined benefit pension items:		
Actuarial losses	\$(4.7)	Cost of sales
Actuarial losses	(3.2)	Selling, general and administrative
Total before taxes	\$(7.9)	
Tax effect	2.5	Income taxes on continuing operations
Amortization of defined benefit pension items, net of tax	\$(5.4)	

L. Net Periodic Benefit Cost — Defined Benefit Plans

Following are the components of net periodic benefit cost for the three and nine months ended September 28, 2013 and September 29, 2012 (in millions):

	Third Quarter Pension Benefits				Other Benefits	
	U.S. Plans		Non-U.S. Plans		All Plans	
	2013	2012	2013	2012	2013	2012
Service cost	\$1.9	\$1.6	\$3.4	\$2.8	\$0.2	\$0.2
Interest cost	13.1	15.6	11.4	11.4	0.7	0.7
Expected return on plan assets	(16.3)	(16.6)	(10.5)	(10.8)	—	—
Amortization of prior service cost (credit)	0.2	0.3	—	0.1	(0.3)	(0.3)
Amortization of net loss	1.5	1.5	1.5	0.8	—	—
Curtailment loss	—	—	—	1.2	—	—

Edgar Filing: LILLY ELI & CO - Form 10-Q

Net periodic cost	\$0.4	\$2.4	\$5.8	\$5.5	\$0.6	\$0.6
-------------------	-------	-------	-------	-------	-------	-------

18

Table of Contents

	Year-to-Date				Other Benefits	
	Pension Benefits		Non-U.S. Plans		All Plans	
	U.S. Plans		Non-U.S. Plans		2013	2012
	2013	2012	2013	2012	2013	2012
Service cost	\$5.8	\$4.9	\$10.4	\$8.6	\$0.6	\$0.7
Interest cost	39.4	46.8	33.3	34.5	1.9	2.1
Expected return on plan assets	(48.8)	(49.8)	(31.4)	(32.5)	—	—
Amortization of prior service cost (credit)	0.8	0.8	0.2	0.3	(1.0)	(0.9)
Amortization of net loss	4.3	4.6	3.8	2.3	—	—
Curtailed (gain) loss	—	—	(0.2)	1.8	—	—
Net periodic cost	\$1.5	\$7.3	\$16.1	\$15.0	\$1.5	\$1.9

M. Fair Value Measurements

FASB ASC 820, Fair Value Measurement, defines, establishes a consistent framework for measuring, and expands disclosure requirements about fair value. ASC 820 requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. These two types of inputs create the following fair value hierarchy:

Level 1 — Quoted prices for identical instruments in active markets.

Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs and significant value drivers are observable.

Level 3 — Instruments that are valued using unobservable inputs.

The Company holds various derivative financial instruments that are employed to manage risks, including foreign currency and interest rate exposures. These financial instruments are carried at fair value and are included within the scope of ASC 820. The Company determines the fair value of derivatives through the use of matrix or model pricing, which utilizes observable inputs such as market interest and currency rates. When determining the fair value of these financial instruments for which Level 1 evidence does not exist, the Company considers various factors including the following: exchange or market price quotations of similar instruments, time value and volatility factors, the Company's own credit rating and the credit rating of the counter-party.

The following table presents the Company's financial assets and liabilities that are measured at fair value on a recurring basis for each of the hierarchy levels (millions of dollars):

	Total Carrying Value	Level 1	Level 2
September 28, 2013:			
Money market fund	\$21.5	\$21.5	\$—
Derivative assets	\$75.6	\$—	\$75.6
Derivative liabilities	\$173.8	\$—	\$173.8
December 29, 2012:			
Money market fund	\$68.0	\$68.0	\$—
Derivative assets	\$99.0	\$—	\$99.0
Derivative liabilities	\$91.5	\$—	\$91.5

The Company had no financial assets or liabilities measured using Level 3 inputs, nor any assets measured at fair value on a non-recurring basis during 2013 and 2012.

Refer to Note I, Derivative Financial Instruments, for more details regarding derivative financial instruments, and Note H, Long-Term Debt and Financing Arrangements, for more information regarding carrying values of the long-term debt shown below.

Table of Contents

The following table presents the carrying values and fair values of the Company's financial assets and liabilities, as well as the Company's debt, as of September 28, 2013 and December 29, 2012 (millions of dollars):

	September 28, 2013		December 29, 2012	
	Carrying Value	Fair Value	Carrying Value	Fair Value
Long-term debt, including current portion	\$3,410.5	\$3,497.5	\$3,536.9	\$3,677.3
Derivative assets	\$75.6	\$75.6	\$99.0	\$99.0
Derivative liabilities	\$173.8	\$173.8	\$91.5	\$91.5

The fair values of long-term debt instruments are considered Level 2 instruments within the fair value hierarchy and are estimated using a discounted cash flow analysis, based on the Company's marginal borrowing rates. The differences in carrying values in long-term debt are attributable to the stated interest rates differing from the Company's marginal borrowing rates. The fair value of the Company's variable rate short-term borrowings approximate their carrying value at September 28, 2013 and December 29, 2012. The fair values of foreign currency and interest rate swap agreements, comprising the derivative assets and liabilities in the table above, are based on current settlement values.

As discussed in Note D, Financing Receivables, the Company has a deferred purchase price receivable related to sales of trade receivables. The deferred purchase price receivable will be repaid in cash as receivables are collected, generally within 30 days, and as such the carrying value of the receivable approximates fair value.

N. Other Costs and Expenses

Other-net is primarily comprised of intangible asset amortization expense, currency related gains or losses, environmental expense and merger and acquisition-related charges, primarily consisting of transaction costs. During the three and nine months ended September 28, 2013, Other-net included \$1.5 million and \$21.0 million in merger and acquisition-related costs, respectively. During the three and nine months ended September 29, 2012, Other-net included \$53.4 million and \$75.0 million in merger and acquisition-related costs, respectively.

O. Restructuring & Asset Impairments

A summary of the restructuring reserve activity from December 29, 2012 to September 28, 2013 is as follows (in millions):

	December 29, 2012	Additions (Reversals), net	Usage	Currency	September 28, 2013
2013 Actions					
Severance and related costs	\$—	\$ 62.0	\$(21.1)) \$0.8	\$41.7
Facility closures	—	10.3	(8.0)) 0.1	2.4
Asset Impairments	—	16.5	(16.5)) —	—
Subtotal 2013 actions	\$—	\$ 88.8	\$(45.6)) \$0.9	\$44.1
Pre-2013 Actions					
Severance and related costs	\$112.1	\$(49.2)	\$(31.6)) \$(0.2)) \$31.1
Facility closures	13.1	1.0	(1.5)) —	12.6
Subtotal Pre-2013 actions	\$125.2	\$(48.2)	\$(33.1)) \$(0.2)) \$43.7
Total	\$125.2	\$ 40.6	\$(78.7)) \$0.7	\$87.8

In the first nine months of 2013, the Company continued with restructuring activities primarily associated with the Black & Decker merger, Niscayah and other acquisitions, and recognized \$40.6 million of net restructuring charges. Of those charges, \$57.1 million relates to severance charges associated with the reduction of approximately 1,000 employees, which was offset by a reversal of \$44.3 million from the termination of a previously approved restructuring action due to a shifting political and economic landscape in certain European countries. Also included in those charges are facility closure costs of \$11.3 million and asset impairment charges of \$16.5 million.

Edgar Filing: LILLY ELI & CO - Form 10-Q

For the three months ended September 28, 2013, the Company recognized \$28.5 million of restructuring charges. Of those charges, \$27.0 million relates to severance charges associated with the reduction of approximately 550 employees and facility closure costs of \$1.5 million.

The majority of the \$87.8 million of reserves remaining as of September 28, 2013 is expected to be utilized within the next 12 months.

20

Table of Contents

Segments: The \$40.6 million of net charges recognized in the first nine months of 2013 includes: \$6.6 million of charges pertaining to the CDIY segment; \$27.0 million of net reserve reductions pertaining to the Industrial segment; \$44.8 million of charges pertaining to the Security segment; and \$16.2 million pertaining to Corporate charges. During the third quarter of 2013, the Company recognized \$28.5 million of restructuring charges including \$5.8 million of charges pertaining to the CDIY segment; \$11.4 million of charges pertaining to the Industrial segment; \$11.6 million of charges pertaining to the Security segment, and \$0.3 million of net reserve reductions pertaining to Corporate.

P. Income Taxes

The Company recognized income tax expense of \$17.3 million and \$80.5 million for the three and nine month periods ended September 28, 2013, respectively, resulting in an effective tax rate of 9.3% and 15.1%, respectively. The effective tax rate differs from the U.S. statutory tax rate for the three and nine month periods ended September 28, 2013 primarily due to a portion of the Company's earnings realized in lower-taxed foreign jurisdictions and the acceleration of certain tax credits resulting in a tax benefit of \$18.5 million in the quarter, the recurring benefit of various foreign business integration structures and the reversal of certain foreign and U.S. state uncertain tax position reserves, related largely to statute expiration.

The Company recognized income tax expense of \$12.9 million and \$82.9 million for the three and nine month periods ended September 29, 2012, respectively, resulting in an effective tax rate of 12.5% and 20.3%, respectively. The effective tax rate differs from the statutory tax rate for the three and nine month periods ended September 29, 2012, primarily due to a portion of the Company's earnings realized in lower-taxed foreign jurisdictions, favorable settlement of certain tax contingencies of \$6.6 million and the realization of a foreign deferred tax asset attributable to the reduction of a valuation allowance for certain net operating losses resulting in a tax benefit of \$7.0 million in the quarter.

During the three months ended September 28, 2013, the Company completed the remaining material 2012 income tax return filings which included the final calculations of the tax gain on the Hardware & Home Improvement business ("HHI") sale which took place in 2012. As a result of these tax return filings, the Company recorded an income tax benefit of approximately \$17.2 million within discontinued operations related to finalization of the taxable gain on the HHI sale. Changes to the original tax gain were driven primarily by the determination of the final purchase price allocation and the finalization of the U.S. tax basis calculation, both of which were finalized in the quarter.

The Company is subject to the examination of its income tax returns by the Internal Revenue Service and other taxing authorities both domestically and internationally. The final outcome of the future tax consequences of these examinations and legal proceedings, as well as, the outcome of competent authority proceedings, changes and interpretation in regulatory tax laws, or expiration of statute of limitations could impact the Company's financial statements. Accordingly, the Company has tax reserves recorded for which it is reasonably possible that the amount of the unrecognized tax benefit will increase or decrease which could have a material effect on the financial results for any particular fiscal quarter or year. However, based on the uncertainties associated with litigation and the status of examinations, including the protocols of finalizing audits by the relevant tax authorities which could include formal legal proceedings, it is not possible to estimate the impact of any such change.

Q. Business Segments

The Company classifies its business into three reportable segments, which also represent its operating segments: Construction & Do It Yourself ("CDIY"), Industrial and Security.

The CDIY segment is comprised of the Professional Power Tool business, the Consumer Products Group, the Hand Tools & Storage business, and the Fastening & Accessories business. The Professional Power Tool business sells professional grade corded and cordless electric power tools and equipment including drills, impact wrenches and drivers, grinders, saws, routers and sanders. The Consumer Products Group sells corded and cordless electric power tools sold under the Black & Decker brand, lawn and garden products and home products. The Hand Tools & Storage business sells measuring and leveling tools, planes, hammers, demolition tools, knives, saws and chisels. The Fastening & Accessories business sells pneumatic tools and fasteners including nail guns, nails, staplers and staples,

concrete and masonry anchors, as well as power tool accessories which include drill bits, router bits, abrasives and saw blades.

The Industrial segment is comprised of the Industrial and Automotive Repair ("IAR"), Engineered Fastening and Infrastructure businesses. The IAR business sells hand tools, power tools, and engineered storage solution products. The Engineered Fastening business primarily sells engineered fastening products and systems designed for specific applications. The product lines include stud welding systems, blind rivets and tools, blind inserts and tools, drawn arc weld studs, engineered plastic and mechanical fasteners, self-piercing riveting systems, precision nut running systems, micro fasteners, and high-strength structural fasteners & plastics. The Infrastructure business consists of the CRC-Evans business and the Company's Hydraulics

Table of Contents

business. The product lines include custom pipe handling machinery, joint welding and coating machinery, weld inspection services and hydraulic tools and accessories.

The Security segment is comprised of the Convergent Security Solutions ("CSS") and the Mechanical Access Solutions ("MAS") businesses. The CSS business designs, supplies and installs electronic security systems and provides electronic security services, including alarm monitoring, video surveillance, fire alarm monitoring, systems integration and system maintenance. Purchasers of these systems typically contract for ongoing security systems monitoring and maintenance at the time of initial equipment installation. The business also includes healthcare solutions, which markets medical carts and cabinets, asset tracking, infant protection, pediatric protection, patient protection, wander management, fall management, and emergency call products. The MAS business sells automatic doors, commercial hardware, locking mechanisms, electronic keyless entry systems, keying systems, tubular and mortise door locksets.

The Company utilizes segment profit, which is defined as net sales minus cost of sales and selling, general, and administrative ("SG&A") inclusive of the provision for doubtful accounts (aside from corporate overhead expense), and segment profit as a percentage of net sales to assess the profitability of each segment. Segment profit excludes the corporate overhead expense element of SG&A, interest income, interest expense, other-net (inclusive of intangible asset amortization expense), restructuring, and income taxes. Refer to Note O, Restructuring & Asset Impairments, for the amount of restructuring charges and asset impairments by segment. Corporate overhead is comprised of world headquarters facility expenses, cost for the executive management team and costs for certain centralized functions that benefit the entire Company but are not directly attributable to the businesses, such as legal and corporate finance functions. Transactions between segments are not material. Segment assets primarily include accounts receivable, inventory, other current assets, property, plant and equipment, intangible assets and other miscellaneous assets.

	Third Quarter		Year-to-Date	
	2013	2012	2013	2012
NET SALES				
CDIY	\$1,387.5	\$1,315.7	\$4,025.7	\$3,819.1
Industrial	771.4	618.0	2,273.1	1,909.1
Security	600.4	583.5	1,796.4	1,760.2
Total	\$2,759.3	\$2,517.2	\$8,095.2	\$7,488.4
SEGMENT PROFIT				
CDIY	\$203.9	\$186.9	\$588.8	\$532.2
Industrial	109.2	94.6	307.5	314.2
Security	61.4	83.1	173.5	224.4
Segment profit	374.5	364.6	1,069.8	1,070.8
Corporate overhead	(56.4)	(61.9)	(179.1)	(184.7)
Other-net	(66.6)	(67.2)	(208.8)	(216.8)
Restructuring and asset impairments	(28.5)	(52.9)	(40.6)	(116.6)
Loss on debt extinguishment	—	(45.5)	—	(45.5)
Interest expense	(39.1)	(36.7)	(118.6)	(105.3)
Interest income	3.0	2.5	9.5	7.3
Earnings from continuing operations before income taxes	\$186.9	\$102.9	\$532.2	\$409.2

During the three and nine months ended September 28, 2013, the Company recorded a total of \$5.1 million and \$26.3 million, respectively, of merger and acquisition-related charges, which reduced segment gross profit, and an additional \$12.2 million and \$30.9 million, respectively, in SG&A primarily for integration costs associated with merger and acquisition-related activities. For the three and nine months ended September 29, 2012, the Company recorded \$11.4 million and \$17.9 million, respectively, of merger and acquisition-related charges, which reduced segment gross profit, and an additional \$16.7 million and \$42.6 million, respectively, in SG&A primarily for integration costs associated with merger and acquisition-related activities. These charges reduced segment profit by \$3.1 million in CDIY, \$2.3 million in Industrial, and \$11.9 million in Security for the three months ended September 28, 2013, and \$17.2 million in CDIY, \$0.6 million in Industrial, and \$10.3 million in Security for the three months ended

Edgar Filing: LILLY ELI & CO - Form 10-Q

September 29, 2012. On a year-to-date basis, segment profit was reduced by \$9.3 million in CDIY, \$20.8 million in Industrial, and \$27.1 million in Security for the nine months ended September 28, 2013, and \$31.0 million in CDIY, \$3.6 million in Industrial, and \$25.9 million in Security for the nine months ended September 29, 2012.

Table of Contents

Corporate overhead for the three and nine months ended September 28, 2013 includes \$19.9 million and \$59.6 million, respectively, of charges pertaining primarily to merger and acquisition-related employee charges and integration costs. For the three and nine months ended September 29, 2012, such charges included in corporate overhead were \$22.5 million and \$57.6 million, respectively.

The following table is a summary of total assets by segment as of September 28, 2013 and December 29, 2012:

	September 28, 2013	December 29, 2012
CDIY	\$8,108.0	\$7,413.3
Industrial	4,722.4	3,451.3
Security	4,504.2	4,600.8
	17,334.6	15,465.4
Discontinued Operations	15.0	171.7
Corporate assets	(325.9) 206.9
Consolidated	\$17,023.7	\$15,844.0

Corporate assets primarily consist of cash, deferred taxes and property, plant and equipment. Based on the nature of the Company's cash pooling arrangements, at times corporate-related cash accounts will be in a net liability position.

R. Commitments and Contingencies

The Company is involved in various legal proceedings relating to environmental issues, employment, product liability, workers' compensation claims and other matters. The Company periodically reviews the status of these proceedings with both inside and outside counsel, as well as an actuary for risk insurance. Management believes that the ultimate disposition of these matters will not have a material adverse effect on operations or financial condition taken as a whole.

The amount recorded for identified contingent liabilities is based on estimates. Amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes available. Actual costs to be incurred in future periods may vary from the estimates, given the inherent uncertainties in evaluating certain exposures.

In connection with the 2010 merger with Black & Decker, the Company assumed certain commitments and contingent liabilities. Black & Decker is a party to litigation and administrative proceedings with respect to claims involving the discharge of hazardous substances into the environment. Some of these assert claims for damages and liability for remedial investigations and clean-up costs with respect to sites that have never been owned or operated by Black & Decker but at which Black & Decker has been identified as a potentially responsible party. Other matters involve current and former manufacturing facilities.

The Environmental Protection Agency ("EPA") and the Santa Ana Regional Water Quality Control Board have each initiated administrative proceedings against Black & Decker and certain of its current or former affiliates alleging that Black & Decker and numerous other defendants are responsible to investigate and remediate alleged groundwater contamination in and adjacent to a 160-acre property located in Rialto, California. The EPA and the cities of Colton and Rialto, as well as Goodrich Corporation, also initiated lawsuits against Black & Decker and certain of its former or current affiliates in the Federal District Court for California, Central District alleging similar claims that Black & Decker is liable under the Comprehensive Environmental Response, Compensation and Liability Act of 1980 ("CERCLA"), the Resource Conservation and Recovery Act, and state law for the discharge or release of hazardous substances into the environment and the contamination caused by those alleged releases. The City of Colton also has a companion case in California State court. The City of Riverside has a similar suit in California State Court with similar claims and the same parties. Both of these cases are currently stayed for all purposes. Certain defendants in that case have cross-claims against other defendants and have asserted claims against the State of California. The administrative proceedings and the lawsuits generally allege that West Coast Loading Corporation ("WCLC"), a defunct company that operated in Rialto between 1952 and 1957, and an as yet undefined number of other defendants are responsible for the release of perchlorate and solvents into the groundwater basin, and that Black & Decker and

certain of its current or former affiliates are liable as a “successor” of WCLC. The Company's settlement discussions among the EPA and numerous other parties progressed throughout late 2012, culminating in the settlement of the EPA's claims against the Company, as well as all other administrative proceedings and lawsuits involving Black & Decker related to the WCLC site, except for the City of Riverside's state court lawsuit. (That lawsuit has been stayed and will, the Company believes, ultimately be rendered moot by the implementation of an interim and final remedy at the site.) This settlement is embodied in a Consent Decree that was filed with the United States District Court for the Central District of California on or about December 4, 2012. The Consent Decree is a public document, and was approved by the Court on July 3, 2013. In substance, Emhart Industries, Inc. (a dissolved, former indirectly wholly-owned subsidiary of The Black & Decker Corporation) (“Emhart”) has agreed to be

Table of Contents

responsible for an interim remedy at the site, which remedy will be funded by (i) amounts received from the EPA in the third quarter of 2013 as gathered from multiple parties and placed in trust, and, to the extent necessary, (ii) Emhart's affiliate. The interim remedy requires the construction of a water treatment facility and the filtering of ground water at or around the Rialto property for a period of approximately 30 years or more.

The EPA has asserted claims in federal court in Rhode Island against certain current and former affiliates of Black & Decker related to environmental contamination found at the Centredale Manor Restoration Project Superfund ("Centredale") site, located in North Providence, Rhode Island. The EPA has discovered a variety of contaminants at the site, including but not limited to, dioxins, polychlorinated biphenyls, and pesticides. The EPA alleges that Black & Decker and certain of its current and former affiliates are liable for site clean-up costs under CERCLA as successors to the liability of Metro-Atlantic, Inc., a former operator at the site, and demanded reimbursement of the EPA's costs related to this site. Black & Decker and certain of its current and former affiliates contest the EPA's allegation that they are responsible for the contamination, and have asserted contribution claims, counterclaims and cross-claims against a number of other potentially responsible parties, including the federal government as well as insurance carriers. The EPA released its Record of Decision ("ROD") in September 2012, which identified and described the EPA's selected remedial alternative for the site. Black & Decker and certain of its current and former affiliates are contesting the EPA's selection of the remedial alternative set forth in the ROD, on the grounds that the EPA's actions were arbitrary and capricious and otherwise not in accordance with law, and have proposed other equally-protective, more cost-effective alternatives. Black & Decker and its affiliate Emhart Industries, Inc. are vigorously litigating the issue of their liability for environmental conditions at the Centredale site. If either or both entities are found liable, the Company's estimated remediation costs related to the Centredale site (including the EPA's past costs as well as costs of additional investigation, remediation, and related costs such as EPA's oversight costs, less escrowed funds contributed by primary potentially responsible parties (PRPs) who have reached settlement agreements with the EPA), which the Company considers to be probable and reasonably estimable, range from approximately \$68.1 million to \$139.7 million, with no amount within that range representing a more likely outcome until such time as the litigation is resolved through judgment or compromise. The Company's reserve for this environmental remediation matter of \$68.1 million reflects the fact that the EPA considers Metro-Atlantic, Inc. to be a primary source of contamination at the site. As the specific nature of the environmental remediation activities that may be mandated by the EPA at this site have not yet been finally determined through the on-going litigation, the ultimate remedial costs associated with the site may vary from the amount accrued by the Company at September 28, 2013.

In the normal course of business, the Company is involved in various lawsuits and claims. In addition, the Company is a party to a number of proceedings before federal and state regulatory agencies relating to environmental remediation. Also, the Company, along with many other companies, has been named as a PRP in a number of administrative proceedings for the remediation of various waste sites, including 31 active Superfund sites. Current laws potentially impose joint and several liabilities upon each PRP. In assessing its potential liability at these sites, the Company has considered the following: whether responsibility is being disputed, the terms of existing agreements, experience at similar sites, and the Company's volumetric contribution at these sites.

The Company's policy is to accrue environmental investigatory and remediation costs for identified sites when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. In the event that no amount in the range of probable loss is considered most likely, the minimum loss in the range is accrued. The amount of liability recorded is based on an evaluation of currently available facts with respect to each individual site and includes such factors as existing technology, presently enacted laws and regulations, and prior experience in remediation of contaminated sites. The liabilities recorded do not take into account any claims for recoveries from insurance or third parties. As assessments and remediation progress at individual sites, the amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes available. As of September 28, 2013 and December 29, 2012, the Company had reserves of \$183.6 million and \$188.0 million, respectively, for remediation activities associated with Company-owned properties, as well as for Superfund sites, for losses that are probable and estimable. Of the 2013 amount, \$12.7 million is classified as current and \$170.9 million as long-term which is expected to be paid over the estimated remediation period. In the third quarter of 2013, the Company recorded the receipt of \$24.3 million in other assets related to funding from the EPA and placed it in trust in

accordance with the Consent Decree associated with WCLC, as previously discussed. Accordingly, the Company's cash obligation as of September 28, 2013 associated with the aforementioned remediation activities is \$159.3 million. The range of environmental remediation costs that is reasonably possible is \$138.3 million to \$274.3 million which is subject to change in the near term. The Company may be liable for environmental remediation of sites it no longer owns. Liabilities have been recorded on those sites in accordance with policy.

The amount recorded for identified contingent liabilities is based on estimates. Amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes available. Actual costs to be incurred in future periods may vary from the estimates, given the inherent uncertainties in evaluating certain exposures. Subject to the imprecision in estimating future contingent liability costs, the Company does not expect that any sum it may have to pay in

Table of Contents

connection with these matters in excess of the amounts recorded will have a materially adverse effect on its financial position, results of operations or liquidity.

S. Guarantees

The Company's financial guarantees at September 28, 2013 are as follows:

(Millions of Dollars)	Term	Maximum Potential Payment	Carrying Amount of Liability
Guarantees on the residual values of leased properties	One to four years	\$26.3	\$—
Standby letters of credit	Up to three years	89.5	—
Commercial customer financing arrangements	Up to six years	17.9	13.9
Total		\$133.7	\$13.9

The Company has guaranteed a portion of the residual value arising from its synthetic lease program. This lease guarantee is for an amount up to \$26.3 million while the fair value of the underlying building is estimated at \$30.8 million. The related assets would be available to satisfy the guarantee obligations and therefore it is unlikely the Company will incur any future loss associated with this guarantee.

The Company provides various limited and full recourse guarantees to financial institutions that provide financing to U.S. and Canadian Mac Tool distributors for their initial purchase of the inventory and trucks necessary to function as a distributor. In addition, the Company provides limited and full recourse guarantees to financial institutions that extend credit to certain end retail customers of its U.S. Mac Tool distributors. The gross amount guaranteed in these arrangements is \$17.9 million and the \$13.9 million carrying value of the guarantees issued is recorded in debt and other liabilities as appropriate in the Condensed Consolidated Balance Sheets.

The Company provides product and service warranties which vary across its businesses. The types of warranties offered generally range from one year to limited lifetime, while certain products carry no warranty. Further, the Company sometimes incurs discretionary costs to service its products in connection with product performance issues. Historical warranty and service claim experience forms the basis for warranty obligations recognized. Adjustments are recorded to the warranty liability as new information becomes available.

The changes in the carrying amount of product and service warranties for the nine months ended September 28, 2013 and September 29, 2012 are as follows:

(Millions of Dollars)	2013	2012
Balance beginning of period	\$124.0	\$124.9
Warranties and guarantees issued	67.3	63.1
Liability assumed from acquisitions	0.1	0.2
Warranty payments and currency	(71.1) (66.7
Balance end of period	\$120.3	\$121.5

T. Parent and Subsidiary Debt Guarantees

The following debt obligations were issued by Stanley Black & Decker, Inc. ("Stanley") and were previously fully and unconditionally guaranteed by The Black & Decker Corporation ("Black & Decker"), a 100.0% owned direct subsidiary of Stanley: 3.40% Notes due 2021; 2.90% Notes due 2022; and the 5.20% 2040 Term Bonds. The following note was issued by Black & Decker and was previously fully and unconditionally guaranteed by Stanley: 5.75% Notes due 2016. During the second quarter of 2013, each guarantor was released from its obligations under the guarantees in accordance with the terms of the indentures governing the underlying obligations. As a result, the Company no longer discloses selected condensed consolidating financial statements of its parent and its guarantor and non-guarantor subsidiaries.

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion contains statements reflecting the Company's views about its future performance that constitute "forward-looking statements" under the Private Securities Litigation Act of 1995. There are a number of important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Please read the information under the caption entitled "Cautionary Statement under the Private Securities Litigation Reform Act of 1995."

Throughout this Management's Discussion and Analysis ("MD&A"), references to Notes refer to the "Notes To (Unaudited) Condensed Consolidated Financial Statements" in Part 1, Item 1 of this Form 10-Q, unless otherwise indicated.

BUSINESS OVERVIEW

Strategy

The Company is a diversified global provider of power and hand tools, mechanical access solutions (i.e. automatic doors and commercial locking systems), electronic security and monitoring systems, and products and services for various industrial applications. The Company is continuing to pursue a diversification strategy that involves industry, geographic and customer diversification to foster sustainable revenue, earnings and cash flow growth. The Company has three primary acquisition growth platforms: Security, Engineered Fastening, and Infrastructure. The Company intends to focus on organic growth across all of its businesses, with the majority of acquisition-related investments being within these three platforms. In addition, the Company plans to increase its presence in emerging markets, with a goal of generating greater than 20% of annual revenues from these markets by 2016/2017.

Refer to the "Strategic Objectives" section of Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Form 10-K for the year ended December 29, 2012 for additional strategic discussions.

Segments

The Company classifies its business into three reportable segments, which also represent its operating segments: Construction & Do-It-Yourself ("CDIY"), Industrial, and Security.

CDIY

The CDIY segment is comprised of the Professional Power Tool business, the Consumer Products Group, which includes outdoor products, the Hand Tools & Storage business, and the Fastening & Accessories business. The segment sells its products to professional end users, distributors and retail consumers. The majority of sales are distributed through retailers, including home centers, mass merchants, hardware stores, and retail lumber yards. Revenues in the CDIY segment were \$4.026 billion for the first three quarters of 2013, representing 50% of the Company's total revenues.

The Professional Power Tool business sells professional grade corded and cordless electric power tools and equipment including drills, impact wrenches and drivers, grinders, saws, routers and sanders.

The Consumer Products Group sells corded and cordless electric power tools sold under the Black & Decker brand, lawn and garden products and home products. Lawn and garden products include hedge trimmers, string trimmers, lawn mowers, edgers, and related accessories. Home products include hand held vacuums and cleaning appliances. The Hand Tools & Storage business sells measuring and leveling tools, planes, hammers, demolition tools, knives, saws and chisels. Storage products include tool boxes, sawhorses and storage units.

The Fastening & Accessories business sells pneumatic tools and fasteners including nail guns, nails, staplers and staples, concrete and masonry anchors, as well as power tool accessories which include drill bits, router bits, abrasives and saw blades.

Industrial

The Industrial segment is comprised of the Industrial and Automotive Repair ("IAR"), Engineered Fastening and Infrastructure businesses. Industrial segment revenues were \$2.273 billion for the first three quarters of 2013, representing 28% of the Company's total revenues.

Table of Contents

The IAR business sells hand tools, power tools, and engineered storage solution products. The business sells to industrial customers in a wide variety of industries and geographies. The products are distributed through third party distributors as well as a direct sales force.

The Engineered Fastening business primarily sells engineered fastening products and systems designed for specific applications. The product lines include stud welding systems, blind rivets and tools, blind inserts and tools, drawn arc weld studs, engineered plastic and mechanical fasteners, self-piercing riveting systems, precision nut running systems, micro fasteners, and high-strength structural fasteners & plastics. The business sells to customers in the automotive, manufacturing, electronics and aerospace industries, amongst others, and its products are distributed through direct sales forces and, to a lesser extent, third party distributors.

The Infrastructure business consists of CRC-Evans and the Company's Hydraulics businesses. The product lines within the Infrastructure business include custom pipe handling machinery, joint welding and coating machinery, weld inspection services and hydraulic tools and accessories. The business sells to the oil and natural gas pipeline industry and other industrial customers. The products and services are primarily distributed through a direct sales force and, to a lesser extent, third party distributors.

Security

The Security segment is comprised of the Convergent Security Solutions ("CSS") and Mechanical Access Solutions ("MAS") businesses. Revenues in the Security segment were \$1.796 billion for the first three quarters of 2013, representing 22% of the Company's total revenues.

The CSS business designs, supplies and installs electronic security systems and provides electronic security services, including alarm monitoring, video surveillance, fire alarm monitoring, systems integration and system maintenance. Purchasers of these systems typically contract for ongoing security systems monitoring and maintenance at the time of initial equipment installation. The business also sells healthcare solutions, which includes medical carts and cabinets, asset tracking solutions, infant protection, pediatric protection, patient protection, wander management, fall management, and emergency call products. The CSS business sells to consumers, retailers, educational, financial and healthcare institutions, as well as commercial, governmental and industrial customers. Products are sold predominantly on a direct sales basis.

The MAS business sells and installs automatic doors, commercial hardware, locking mechanisms, electronic keyless entry systems, keying systems, tubular and mortise door locksets. MAS sells to commercial customers primarily through direct and independent distribution channels.

Acquisitions

2013 Acquisitions

During the first nine months of 2013, the Company completed six acquisitions for a total purchase price of \$908.5 million, net of cash acquired. The largest of these acquisitions was Infastech, which was purchased for \$826.4 million, net of cash acquired. Infastech designs, manufactures and distributes highly engineered fastening technologies and applications for a diverse blue-chip customer base in the industrial, electronics, automotive, construction and aerospace end markets. Infastech is headquartered in Hong Kong and is being consolidated into the Company's Engineered Fastening business within the Industrial segment. The Company also purchased a 60% controlling share in Jiangsu Guoqiang Tools ("GQ") for \$48.5 million, net of cash acquired. The fair value of the non-controlling interest of GQ is \$34.4 million. GQ is China's third largest power tools and spare parts manufacturer and distributor and is a strategic step in driving the expansion of the Company's emerging market growth platform. GQ is being consolidated into the Company's CDIY segment.

2012 Acquisitions

During 2012, the Company completed seven acquisitions for a total purchase price of \$696.0 million, net of cash acquired. The largest of these acquisitions were AeroScout Inc. ("AeroScout"), which was purchased for \$238.8 million, net of cash acquired, and Powers Fasteners, Inc. ("Powers"), which was purchased for \$220.5 million, net of cash acquired. AeroScout develops, manufactures, and sells Real-Time Locating Systems ("RTLS") primarily to healthcare and certain industrial customers. Powers distributes fastening products such as mechanical anchors, adhesive anchoring systems, and powered forced-entry systems, mainly for commercial construction end customers. AeroScout has been integrated within the Security and Industrial segments while Powers is part of the CDIY segment.

Table of Contents

Five smaller acquisitions were completed during 2012 for a total purchase price of \$236.7 million. The largest of these acquisitions were Lista North America ("Lista"), which was purchased for \$89.7 million, net of cash acquired, and Tong Lung Metal Industry Co. ("Tong Lung"), which the Company purchased for \$114.8 million, net of cash acquired, and assumed \$20.1 million of short-term debt. Lista's storage and workbench solutions complement the IAR division's tool, storage, radio frequency identification ("RFID") enabled systems, and specialty supply product and service offerings. Tong Lung manufactures and sells commercial and residential locksets. The residential portion of the Tong Lung business was sold in 2013 in connection with the December 2012 sale of the Hardware & Home Improvement business ("HHI"), which is discussed in further detail below. Lista has been integrated within the Industrial segment while Tong Lung is part of the Security segment.

Divestitures

HHI and Tong Lung Residential Divestiture

In December 2012, the Company sold HHI to Spectrum Brands Holdings, Inc. ("Spectrum") for approximately \$1.4 billion in cash. HHI is a provider of residential locksets, residential builders hardware and plumbing products marketed under the Kwikset, Weiser, Baldwin, Stanley, National and Pfister brands. The majority of the HHI business was part of the Company's Security segment, with the remainder being part of the Company's CDIY segment. The divestiture of the HHI business is part of the continued diversification of the Company's revenue streams and geographic footprint consistent with the Company's strategic framework.

The purchase and sale agreement stipulated that the sale occur in a First and Second Closing, for approximately \$1.3 billion and approximately \$94 million, respectively. The First Closing, which excluded the residential portion of the Tong Lung business, occurred on December 17, 2012. The Second Closing, covering the residential portion of the Tong Lung business, occurred on April 8, 2013. The operating results of the residential portion of Tong Lung have been reported as discontinued operations through April 8, 2013 as well as the three and nine months ended September 29, 2012, while the operating results of HHI have been reported as discontinued operations for the three and nine months ended September 29, 2012.

The net proceeds from this divestiture were used to repurchase \$850 million of the Company's common stock and for debt reduction, to ensure the Company's leverage ratios remain in its target range. The Company used existing sources of liquidity to fund the Infastech acquisition.

During the third quarter of 2013, the Company classified two small businesses within the Security and Industrial segments as held for sale based on management's intention to sell these businesses. The operating results of these businesses, including the related impairment losses, have been reported as discontinued operations for all periods presented.

Certain Items Impacting Earnings

Throughout MD&A, the Company has provided a discussion of the outlook and results both inclusive and exclusive of the merger and acquisition-related charges. Merger and acquisition-related charges pertain primarily to the Black & Decker merger and the Niscayah and Infastech acquisitions. The amounts and measures, including gross profit and segment profit, on a basis excluding such charges are considered relevant to aid analysis and understanding of the Company's results aside from the material impact of these charges. In addition, these measures are utilized internally by management to understand business trends, as once the aforementioned anticipated cost synergies from the Black & Decker merger and other acquisitions are realized, such charges are not expected to recur. The merger and acquisition-related charges are as follows:

Third Quarter and Year-To-Date 2013 Merger and Acquisition-Related Charges

The Company reported \$67 million and \$179 million in pre-tax charges in the third quarter and year-to-date 2013 periods, respectively, pertaining to merger and acquisition-related charges, which were comprised of the following: \$5 million and \$27 million for the third quarter and year-to-date 2013 periods, respectively, reducing Gross Profit pertaining mainly to integration-related matters and amortization of the inventory step-up adjustment for the Infastech acquisition;

\$32 million and \$90 million for the third quarter and year-to-date 2013 periods, respectively, in SG&A primarily for integration-related administrative costs and consulting fees, as well as employee related matters;

•

\$1 million and \$21 million for the third quarter and year-to-date 2013 periods, respectively, in Other, net predominately for deal transaction costs; and

\$29 million and \$41 million for the third quarter and year-to-date 2013 periods, respectively, in restructuring charges primarily for Niscayah-related restructuring charges and cost containment actions associated with the severance of employees, which are partially offset by a \$44 million reversal in the second quarter of 2013 from the termination of a

Table of Contents

previously approved restructuring action due to a shifting political and economic landscape in certain European countries.

The tax effect on the above net charges during the third quarter of 2013 was \$16 million, resulting in after-tax charges of \$51 million, or \$0.32 per diluted share. On a year-to-date basis, the tax effect on the above charges was \$50 million, resulting in after-tax merger and acquisition-related charges of \$129 million, or \$0.81 per diluted share.

Third Quarter and Year-To-Date 2012 Merger and Acquisition-Related Charges

The Company reported \$157 million and \$311 million in pre-tax charges in the third quarter and year-to-date 2012 periods, pertaining to merger and acquisition-related charges which were comprised of the following:

- \$12 million and \$18 million for the third quarter and year-to-date 2012 periods, respectively, reducing Gross Profit primarily relating to facility closure-related charges;

- \$39 million and \$100 million for the third quarter and year-to-date 2012 periods, respectively, in SG&A primarily for integration-related administrative costs, consulting fees, and employee related matters;

- \$8 million and \$30 million for the third quarter and year-to-date 2012 periods, respectively, in Other, net predominately for transaction costs;

- \$45 million for the third quarter and year-to-date 2012 periods, in Loss on debt extinguishment, associated with the loss on extinguishment of \$900.0 million of debt maturities; and

- \$53 million and \$118 million for the third quarter and year-to-date 2012 periods, respectively, in restructuring charges primarily for Niscayah-related restructuring charges and cost containment actions associated with the severance of employees.

The tax effect on the above charges during the third quarter of 2012 was \$44 million, resulting in after-tax charges of \$113 million, or \$0.68 per diluted share. On a year-to-date basis, the tax effect on the above charges was \$77 million, resulting in after-tax charges of \$234 million, or \$1.40 per diluted share.

Revision Of 2013 Outlook

This outlook discussion is intended to provide broad insight into the Company's near-term earnings and cash flow generation prospects. The Company is revising its outlook for full year 2013 diluted earnings per share to approximately \$3.75 - \$3.95 (from previous \$4.46 - \$4.71), inclusive of \$225 - \$250 million of pre-tax merger and acquisition-related charges. Excluding such charges, 2013 earnings per dilutive share is now expected to be in the range of \$4.90 - \$5.00 (from previous \$5.40 - \$5.65). The Company expects free cash flow, excluding merger & acquisition-related charges and payments, to approximate \$800 million. Approximately half of the full year EPS outlook reduction relates to a slower than expected pace of Security margin improvement from first half 2013 levels as the business overcomes the cost challenges of the Niscayah integration. The remaining reduction relates to lower growth expectations within the CDIY and Industrial segments, which is primarily attributable to growth pressure within the emerging markets due to the current macroeconomic environment as well as the uncertainty created by the U.S. government's sequestration and recent shut-down, and its impact on business, consumer confidence and spending levels. These factors are partially offset by a lower expected tax rate, excluding merger and acquisition-related charges, of approximately 20%, compared to the previously estimated tax rate of 23%. Organic net sales are now expected to increase approximately 3% from 2012, compared to previous estimates of 4-5%. All other assumptions remain unchanged from the guidance previously provided.

As mentioned previously, the Company has decided to intensify its focus on increasing organic growth, concentrated in six major areas during the next few years: (1) increase presence in emerging markets in the Power Tools, Hand Tools and Commercial Hardware mid-price point categories, (2) create a "smart" tools and storage market using radio frequency identification ("RFID") and real-time locating system ("RTLS") technology, (3) leverage the AeroScout RTLS capability into the electronic security market including the acute care vertical within the Company's Healthcare business, (4) expand the Company's market penetration with U.S. government customers in the Healthcare, Security, and Industrial verticals, (5) increase offshore oil and gas pipeline service revenue in the Company's CRC-Evans business, and (6) continue to identify and realize revenue synergies associated with the Black & Decker Merger. Over the next three years, the Company will invest approximately \$150 million (\$100 million of recurring annual operating expense and \$50 million of capital) to support these initiatives. The Company expects that investment and achievement in these growth areas will generate approximately \$850 million of incremental revenue and \$200 million

of incremental operating profit over the same three year period which will assist the Company in the achievement of its long-term goal of 4-6% organic growth.

Table of Contents**RESULTS OF OPERATIONS**

Net Sales: Net sales were \$2.759 billion in the third quarter of 2013 compared to \$2.517 billion in the third quarter of 2012, representing an increase of \$242.1 million, or 10%. Acquisitions and volume provided increases of 7% and 5% in net sales, respectively, which was offset by a 1% decrease in price and a 1% decrease related to the impacts of foreign currency fluctuations. In the CDIY segment, organic sales increased 5% compared to the third quarter of 2012, as a result of strong organic volume in North America, primarily driven by promotions, new product introductions and a strengthening residential construction market, as well as 10% organic growth within the emerging markets. Europe volumes were up 3% despite persistent unfavorable economic conditions. In the Industrial segment, organic sales increased 4% relative to the third quarter of 2012, which was mainly attributable to organic sales increases in Infrastructure of 23% as a result of onshore volume growth, as well as a 2% increase in organic sales for the IAR business due to volume growth in North America and the emerging markets offsetting weak government sales. In the Security segment, sales increased approximately 3% compared to the third quarter of 2012, mainly due to a 1% increase in price, a 1% increase related to the impacts of foreign currency fluctuations and a 1% increase related to acquisitions. CSS Europe experienced a 4% decline in organic growth due to pressure in various regions, which partially offset the 6% organic growth in the CSS North America business driven by higher installation and service volumes supported by early success with the vertical markets organic growth initiative.

From a geographic standpoint organic growth across all segments resulted in a 2% decline in Europe, while North America had 5% growth in both the US and Canada. Emerging markets increased 11% overall, primarily driven by 10% growth in Latin America.

On a year-to-date basis, net sales totaled \$8.095 billion, up 8%, compared to \$7.488 billion in the first nine months of 2012. Acquisitions and volume provided increases of 6% and 3% in net sales respectively, which was partially offset by unfavorable effects of foreign currency fluctuations resulting in a 1% decrease. Net sales growth in the first nine months of 2013 was mainly driven by CDIY, which achieved 4% organic growth due to strong results in North America and emerging markets, and the Industrial segment, which grew 4% organically as a result of strong performances by the Infrastructure and Engineered Fastening businesses.

Gross Profit: Gross profit was \$987.7 million in the third quarter of 2013 compared to \$911.9 million in the third quarter of 2012, or 35.8% and 36.2% of net sales for each quarter, respectively. Merger and acquisition-related charges, which reduced gross profit, were approximately \$5 million in the third quarter of 2013 and \$12 million in the third quarter of 2012. Excluding these merger and acquisition-related charges, gross profit was 36.0% of net sales in 2013 compared to 36.7% of net sales in the prior year. The decrease in the profit rate year over year reflects favorable impacts of volume and cost synergies, which were more than offset by margin contraction within the Security business caused by negative revenue mix and field inefficiency.

Year-to-date gross profit was \$2.902 billion, or 35.9% of net sales, compared to \$2.749 billion, or 36.7% of net sales, for the nine month periods ended September 28, 2013 and September 29, 2012, respectively. Merger and acquisition-related charges, which reduced gross profit, were approximately \$26 million in the nine months of 2013 and approximately \$18 million in the first nine months of 2012. Excluding these charges, gross profit was 36.2% of net sales in 2013 and 37.0% of net sales in 2012. The year-to-date decrease in the profit rate is due to favorable cost synergies and higher volumes, which were more than offset by margin contractions in the Industrial and Security segments.

SG&A Expenses: SG&A, inclusive of the provision for doubtful accounts, was \$669.6 million, or 24.3% of net sales, in the third quarter of 2013 compared to \$609.2 million, or 24.2% of net sales, in the third quarter of 2012. Within SG&A, merger and acquisition-related compensation costs and integration-related expenses totaled approximately \$32 million and \$39 million, respectively, for the third quarter of 2013 and 2012. Excluding these merger and acquisition-related charges, SG&A was 23.1% of net sales in 2013 compared to 22.7% of net sales in the prior year. The increase reflects the additional operating expenses associated with the organic growth initiatives.

On a year-to-date basis, SG&A, inclusive of the provision for doubtful accounts, was \$2.012 billion, or 24.8% of net sales, in 2013 compared to \$1.863 billion, or 24.9% of net sales, in 2012. Excluding merger and acquisition-related charges of approximately \$90 million and \$100 million, respectively, during the first nine months of 2013 and 2012,

SG&A was 23.7% and 23.5% of net sales, respectively.

Distribution center costs (i.e. warehousing and fulfillment facility and associated labor costs) are classified within SG&A. This classification may differ from other companies who may report such expenses within cost of sales. Due to diversity in practice, to the extent the classification of these distribution costs differs from other companies, the Company's gross margins may not be comparable.

Corporate Overhead: The corporate overhead element of SG&A, which is not allocated to the business segments, amounted to \$56.4 million, or 2% of net sales, in the third quarter of 2013 and \$61.9 million, or 2.5% of net sales, in the third quarter of

Table of Contents

2012. Excluding merger and acquisition-related charges, the corporate overhead element of SG&A was \$36.5 million, or 1.3% of net sales, in the third quarter of 2013 compared to \$39.4 million, or 1.6% of net sales, in the third quarter of 2012.

On a year-to-date basis, the corporate overhead element of SG&A amounted to \$179.1 million, or 2.2% of net sales, in 2013 compared to \$184.7 million, or 2.5% of net sales, in the corresponding period of 2012. Excluding merger and acquisition-related charges, the corporate overhead element of SG&A was \$119.5 million, or 1.5% of net sales, and \$127.1 million, or 1.7% of net sales, for the first nine months of 2013 and 2012, respectively.

Other, net: Other, net expense amounted to \$66.6 million in the third quarter of 2013 versus \$67.2 million in the third quarter of 2012. The decrease was primarily driven by a reduction in merger and acquisition-related costs partially offset by an increase in amortization expense. On a year-to-date basis, Other, net expense was \$208.8 million in 2013 as compared with \$216.8 million in 2012. The change was primarily driven by reduced negative impacts of foreign currency partially offset by an increase in amortization expense.

Loss on debt extinguishment: In the third quarter of the 2012, the Company recorded a net pre-tax loss of \$45 million associated with the extinguishment of \$900.0 million of debt maturities.

Interest, net: Net interest expense in the third quarter of 2013 was \$36.1 million versus \$34.2 million in 2012. On a year-to-date basis, net interest expense was \$109.1 million compared to \$98.0 million in the prior year. The increase in net interest expense for both the quarter-to-date and year-to-date periods is primarily driven by the debt issuances in the second half of 2012, partially offset by the debt extinguished in the third quarter of 2012.

Income Taxes: The Company recognized income tax expense of \$17.3 million and \$80.5 million for the three and nine month periods ended September 28, 2013, respectively, resulting in an effective tax rate of 9.3% and 15.1%, respectively. The effective tax rate differs from the U.S. statutory tax rate for the three and nine month periods ended September 28, 2013, primarily due to a portion of the Company's earnings realized in lower-taxed foreign jurisdictions, the acceleration of certain tax credits, the recurring benefit of various foreign business integration structures and the reversal of certain foreign and U.S. state uncertain tax position reserves, related largely to statute expiration.

The Company recognized income tax expense of \$12.9 million and \$82.9 million for the three and nine month periods ended September 29, 2012, respectively, resulting in an effective tax rate of 12.5% and 20.3%, respectively. The effective tax rate differs from the U.S. statutory tax rate for the three and nine month periods ended September 29, 2012, primarily due to a portion of the Company's earnings realized in lower-taxed foreign jurisdiction, the favorable settlement of certain tax contingencies which resulted in a net \$6.6 million tax benefit and the realization of a foreign deferred tax asset attributable to the reduction of a valuation allowance for certain net operating losses resulting in a tax benefit of \$7.0 million in the quarter.

Business Segment Results

The Company's reportable segments are aggregations of businesses that have similar products, services and end markets, among other factors. The Company utilizes segment profit (which is defined as net sales minus cost of sales and SG&A aside from corporate overhead expense), and segment profit as a percentage of net sales to assess the profitability of each segment. Segment profit excludes the corporate overhead expense element of SG&A, Other-net (inclusive of intangible asset amortization expense), restructuring charges, interest income, interest expense, and income tax expense. Corporate overhead is comprised of world headquarters facility expense, cost for the executive management team and the expense pertaining to certain centralized functions that benefit the entire Company but are not directly attributable to the businesses, such as legal and corporate finance functions. Refer to Note O, Restructuring & Asset Impairments of the Notes to (Unaudited) Condensed Consolidated Financial Statements for the amount of restructuring charges and asset impairments attributable to each segment. As discussed previously, the Company's operations are classified into three business segments, which also represent its operating segments: CDIY, Industrial and Security.

CDIY:

Edgar Filing: LILLY ELI & CO - Form 10-Q

(Millions of Dollars)	Third Quarter		Year-to-Date		
	2013	2012	2013	2012	
Net sales	\$1,387.5	\$1,315.7	\$4,025.7	\$3,819.1	
Segment profit	\$203.9	\$186.9	\$588.8	\$532.2	
% of Net sales	14.7	% 14.2	% 14.6	% 13.9	%

31

Table of Contents

CDIY net sales increased \$71.8 million, or 5%, in the third quarter of 2013 compared to the third quarter of 2012. The increase was driven by a 6% increase in volume and a 1% increase in acquisitions, partially offset by a 1% decrease in price and a 1% decline due to unfavorable changes in foreign currency translation. Organic sales increased 5% from the third quarter of 2012 as a result of strong organic volume in North America, which was primarily driven by promotions, new product introductions and a strengthening residential construction market. The segment also realized 10% organic growth in emerging markets as a result of growing penetration in connection with the Company's growth initiatives. Europe volumes increased 3% due to new product introductions and customer share gains despite persistent unfavorable economic conditions.

On a year-to-date basis, net sales increased \$206.6 million, or 5%, for 2013 compared to the same period of 2012. Organic sales increased 4% primarily due to the strong results in North America partially offset by modest volume pressures in Europe. Volumes were up 5% and acquisitions contributed 2% of sales growth, which was partially offset by a 1% decline in both pricing and unfavorable changes in foreign currency translation.

Segment profit for the third quarter of 2013 was \$203.9 million, or 14.7% of net sales, compared to \$186.9 million, or 14.2% of net sales, in the third quarter of 2012. Excluding merger and acquisition-related charges of \$3.1 million for the third quarter of 2013, segment profit totaled \$207.0 million, or 14.9% of net sales, for the third quarter of 2013 compared to \$204.1 million, or 15.5% of net sales, in the third quarter of 2012 (excluding \$17.2 million in merger and acquisition-related charges). The decrease in the segment profit rate is attributed to cost synergies and improved volume, which were more than offset by the additional operating expenses associated with the organic growth initiatives.

Year-to-date segment profit for CDIY was \$588.8 million, or 14.6% of net sales, compared to \$532.2 million, or 13.9% of net sales, for the corresponding 2012 period. Excluding \$9.2 million in merger and acquisition-related charges, segment profit amounted to \$598.0 million, or 14.9% of net sales, in 2013 compared to \$563.2 million, or 14.7%, in 2012 (excluding \$31.0 million in merger and acquisition-related charges). The segment profit rate improved on a year-to-date basis due to cost synergies, higher volumes, and improved productivity in business operations, which was partially offset by the additional operating expenses associated with the organic growth initiatives.

Industrial:

(Millions of Dollars)	Third Quarter		Year-to-Date		
	2013	2012	2013	2012	
Net sales	\$771.4	\$618.0	\$2,273.1	\$1,909.1	
Segment profit	\$109.2	\$94.6	\$307.5	\$314.2	
% of Net sales	14.2	% 15.3	% 13.5	% 16.5	%

Industrial sales increased \$153.4 million, or 25%, in the third quarter of 2013 from \$618.0 million in the third quarter of 2012. The increase was primarily driven by the Infastech acquisition, which increased sales by 22%, and volume increases of 4%, partially offset by a 1% decline due to unfavorable changes in foreign currency translation. Organic sales increased 4% from the third quarter of 2012 due to a combination of factors. Engineered Fastening experienced flat organic growth in the third quarter. IAR grew 2% organically as a result of volume increases in North America, which was driven by strong MRO vending sales and growth in the Mac Tools mobile distribution business, and emerging markets. Organic sales for the Infrastructure business increased 23% due to strength in the North American oil and gas onshore business.

Year-to-date sales were \$2,273.1 million, a 19% increase from 2012 sales of \$1,909.1 million, primarily due to the Infastech acquisition which increased sales by 17%. The remaining increase was driven by volume growth of 3%, partially offset by a 1% decline due to unfavorable foreign currency translation. Net sales growth in the first nine months of 2013 was mainly attributable to continued growth in the automotive business within Engineered Fastening and strong organic growth in the Infrastructure business, primarily related to the oil and gas onshore and offshore businesses. IAR organic sales were relatively flat in the first nine months of 2013 as strong results in emerging markets were offset by volume declines in Europe.

Industrial segment profit for the third quarter of 2013 was \$109.2 million, or 14.2% of net sales, compared to \$94.6 million, or 15.3% of net sales, in the third quarter of 2012. Excluding \$2.3 million in merger and acquisition-related charges, segment profit was \$111.5 million, or 14.5% of net sales, in the third quarter of 2013 and \$95.2 million, or

15.4% of net sales, in the third quarter of 2012 (excluding \$0.6 million in merger and acquisition-related charges). The decrease in segment profit rate is primarily attributed to the additional operating expenses associated with the organic growth initiatives and the impact of modestly below line average Infastech margins.

On a year-to-date basis, Industrial segment profit totaled \$307.5 million, or 13.5% of net sales, in the first nine months of 2013 compared to \$314.2 million, or 16.5% of net sales, in the first nine months of 2012. Excluding \$20.8 million in merger and

Table of Contents

acquisition-related charges, segment profit was \$328.3 million, or 14.4% of net sales, in the first nine months of 2013 and \$317.8 million, or 16.6% of net sales, in the first nine months of 2012 (excluding \$3.6 million in merger and acquisition-related charges). The decrease in segment profit rate is primarily attributed to lower volumes in IAR Europe, the additional operating expenses associated with the organic growth initiatives and the impact of the above noted Infatech margins.

Security:

(Millions of Dollars)	Third Quarter		Year-to-Date		
	2013	2012	2013	2012	
Net sales	\$600.4	\$583.5	\$1,796.4	\$1,760.2	
Segment profit	\$61.4	\$83.1	\$173.5	\$224.4	
% of Net sales	10.2	% 14.2	% 9.7	% 12.7	%

Security net sales increased \$16.9 million, or 3%, in the third quarter of 2013 from \$583.5 million in the third quarter of 2012. Pricing, acquisitions and foreign currency translation increased net sales each by 1%. From a geographic standpoint, stronger end markets in North America were partially offset by volume declines in Europe. The CSS North America business posted solid organic revenue growth of 6%, while CSS Europe declined 4% organically due to continued pressure primarily within France and the Nordics. MAS organic sales were up 4% as a result of strong growth within the automatic door business due to successful door conversion wins and new product introductions and growth in the commercial mechanical lock business in the emerging markets.

On a year-to-date basis, net sales increased \$36.2 million, or 2%, in the first nine months of 2013 from the first nine months of 2012, primarily due to the same factors that impacted the third quarter.

Segment profit for the third quarter of 2013 was \$61.4 million, or 10.2% of net sales, compared to \$83.1 million, or 14.2% of net sales, in the third quarter of 2012. Excluding merger and acquisition-related charges of \$11.9 million, segment profit amounted to \$73.3 million, or 12.2% of net sales, in the third quarter of 2013 compared to \$93.4 million, or 16.0% of net sales, in the third quarter of 2012 (excluding \$10.3 million in merger and acquisition-related charges). The decline in segment profit is attributed to planned growth investments in vertical solutions and emerging markets, new product development, investments in field technicians in North America and impacts of lower recurring revenue volume in Europe.

On a year-to-date basis segment profit was \$173.5 million, or 9.7% of net sales, in the first nine months of 2013 compared to \$224.4 million, or 12.7% of net sales, in the first nine months of 2012. Excluding merger and acquisition related charges of \$27.1 million, segment profit amounted to \$200.6 million, or 11.2% of net sales, in the first nine months of 2013 compared to segment profit of \$250.3 million, or 14.2% of net sales, in the first nine months of 2012 (excluding \$25.9 million in merger and acquisition-related charges). The year-to-date decrease in the segment profit rate is due to the same factors that impacted the third quarter.

RESTRUCTURING ACTIVITIES

A summary of the restructuring reserve activity from December 29, 2012 to September 28, 2013 is as follows (in millions):

	December 29, 2012	Additions (Reversals), net	Usage	Currency	September 28, 2013
2013 Actions					
Severance and related costs	\$—	\$ 62.0	\$(21.1)) \$0.8	\$41.7
Facility closures	—	10.3	(8.0)) 0.1	2.4
Asset Impairments	—	16.5	(16.5)) —	—
Subtotal 2013 actions	\$—	\$ 88.8	\$(45.6)) \$0.9	\$44.1
Pre-2013 Actions					
Severance and related costs	\$112.1	\$(49.2)	\$(31.6)) \$(0.2)) \$31.1
Facility closures	13.1	1.0	(1.5)) —	12.6
Subtotal Pre-2013 actions	\$125.2	\$(48.2)	\$(33.1)) \$(0.2)) \$43.7
Total	\$125.2	\$ 40.6	\$(78.7)) \$0.7	\$87.8

In the first nine months of 2013, the Company continued with restructuring activities primarily associated with the Black & Decker merger, Niscayah and other acquisitions, and recognized \$40.6 million of net restructuring charges. Of those charges, \$57.1 million relates to severance charges associated with the reduction of approximately 1,000 employees, which was offset by a reversal of

Table of Contents

\$44.3 million from the termination of a previously approved restructuring action due to a shifting political and economic landscape in certain European countries. Also included in those charges are facility closure costs of \$11.3 million and asset impairment charges of \$16.5 million.

For the three months ended September 28, 2013, the Company recognized \$28.5 million of restructuring charges. Of those charges, \$27.0 million relates to severance charges associated with the reduction of approximately 550 employees and facility closure costs of \$1.5 million.

The majority of the \$87.8 million of reserves remaining as of September 28, 2013 is expected to be utilized within the next 12 months.

Segments: The \$40.6 million of net charges recognized in the first nine months of 2013 includes: \$6.6 million of charges pertaining to the CDIY segment; \$27.0 million of net reserve reductions pertaining to the Industrial segment; \$44.8 million of charges pertaining to the Security segment; and \$16.2 million pertaining to Corporate charges.

During the third quarter of 2013, the Company recognized \$28.5 million of restructuring charges including \$5.8 million of charges pertaining to the CDIY segment; \$11.4 million of charges pertaining to the Industrial segment; \$11.6 million of charges pertaining to the Security segment, and \$0.3 million of net reserve reductions pertaining to Corporate.

FINANCIAL CONDITION

Liquidity, Sources and Uses of Capital: The Company's primary sources of liquidity are cash flows generated from operations and available lines of credit under various credit facilities. The Company's cash flows are presented on a consolidated basis and include cash flows from discontinued operations.

Operating Activities: Cash flow provided by operations was \$99.6 million in the third quarter of 2013 and \$151.2 million in the third quarter of 2012. The cash flows from operations were negatively impacted by merger and acquisition-related charges and payments of \$52.7 million and \$83.5 million in the third quarter of 2013 and 2012, respectively. Cash outflows from working capital (accounts receivable, inventory, accounts payable and deferred revenue) were \$244.3 million in the third quarter of 2013 compared to \$174.8 million in the third quarter of 2012. The change in working capital cash flows was primarily driven by higher inventory purchases associated with inventory build for the fourth quarter and higher accounts receivables caused by timing of sales within the quarter, partially offset by higher payable balances.

Year-to-date cash flow provided by operations was \$136.3 million in the first nine months of 2013 compared to \$418.1 million in the corresponding period of 2012. Cash outflows from working capital were \$371.6 million in 2013 compared to \$286.0 million in 2012, primarily due to timing of revenue during 2013 resulting in temporary additional working capital pressures. Additionally, merger and acquisition-related charges and payments were \$223.7 million compared to \$212.2 million in the first nine months of 2013 and 2012, respectively. Operating cash flows in 2013 were also negatively impacted by employee related payments and the timing of employee benefit plan contributions.

Free Cash Flow: Free cash flow, as defined in the following table, was \$5.4 million in the third quarter of 2013 compared to \$62.2 million in the corresponding 2012 period. Free cash flow on a year-to-date basis was an outflow of \$125.8 million in 2013 compared to an inflow of \$158.6 million in 2012. Management considers free cash flow an important indicator of its liquidity, as well as its ability to fund future growth and provide a dividend to shareowners. Free cash flow does not include deductions for mandatory debt service, other borrowing activity, discretionary dividends on the Company's common stock and business acquisitions, among other items.

(Millions of Dollars)	Third Quarter		Year-to-Date	
	2013	2012	2013	2012
Net cash provided by operating activities	\$99.6	\$151.2	\$136.3	\$418.1
Less: capital expenditures	(94.2)	(89.0)	(262.1)	(259.5)
Free cash inflow (outflow)	\$5.4	\$62.2	\$(125.8)	\$158.6

When merger and acquisition-related charges and payments of \$65.6 million and \$282.3 million for the three and nine months ended September 28, 2013, respectively, are added back to the Company's free cash flows, the resulting amounts are free cash flows of \$71.0 million and \$156.5 million, respectively. When merger and acquisition-related charges and payments of \$106.7 million and \$304.2 million for the three and nine months ended September 29, 2012, respectively, are added back to the Company's free cash flows, the resulting amounts are free cash flows of \$168.9 million and \$462.8 million, respectively.

Table of Contents

Based on its ability to generate cash flow from operations on an annual basis and credit position at September 28, 2013, the Company believes over the long term it has the financial flexibility to deploy excess capital to its shareowners' advantage through a combination of acquisitions, dividends, and potential future share repurchases.

Investing Activities: Cash flow used in investing activities was \$104.6 million in the third quarter of 2013 compared to \$188.3 million in the third quarter of 2012. Year-to-date cash flows used in investing activities were \$1,085.2 million and \$934.2 million in the first nine months of 2013 and 2012, respectively. Capital and software expenditures were \$94.2 million (inclusive of \$12.9 million for merger and acquisition-related capital expenditures) in the third quarter of 2013 compared to \$89.0 million (inclusive of \$23.2 million for merger and acquisition-related capital expenditures) of capital expenditures in the third quarter of 2012. Year-to-date capital and software expenditures were \$262.1 million (inclusive of \$58.6 million for merger and acquisition-related capital expenditures) and \$259.5 million (inclusive of \$92.0 million for merger and acquisition-related capital expenditures) in the first nine months of 2013 and 2012, respectively. The Company continues to invest in productivity and cost structure improvements, as well as achieving merger and acquisition-related cost synergies, while ensuring that such investments provide an appropriate return on capital employed.

Cash outflows for business acquisitions were \$16.7 million in the third quarter of 2013, which was primarily related to two smaller acquisitions in the Company's CDiY and Industrial segments, compared to \$106.4 million in the third quarter of 2012, primarily relating to the purchase of Tong Lung. On a year-to-date basis, cash outflows for business acquisitions were \$926.6 million and \$695.1 million for 2013 and 2012, respectively. The majority of cash outflows during 2013 related to the acquisitions of Infastech for \$826.4 million, net of cash acquired, and Jiangsu Guoqiang Tools ("GQ"), in which the Company purchased a 60% controlling share for \$48.5 million, net of cash acquired. The majority of cash outflows during 2012 related to the acquisitions of Powers, AeroScout and Tong Lung.

Financing Activities: Cash flow used in financing activities was \$106.5 million in the third quarter of 2013 compared to cash inflows of \$209.0 million in the third quarter of 2012. Net repayments of short-term borrowings under the Company's commercial paper program were \$70.9 million in the third quarter of 2013 compared to net proceeds from short-term borrowings of \$527.4 million in the third quarter of 2012. Cash proceeds from the issuances of common stock were \$32.3 million and \$27.4 million in the third quarter of 2013 and 2012, respectively. Repayments on long-term debt were \$0.6 million in the third quarter of 2013 compared to \$900.9 million in the third quarter of 2012. Cash dividends were \$77.5 million in the third quarter of 2013 compared to \$82.5 million in the third quarter of 2012. During the third quarter of 2012, the Company received \$729.4 million of net proceeds relating to the issuance of junior subordinated debentures and paid a premium of \$91.0 million relating to the repurchase of three debt instruments with total outstanding principal of \$900.0 million.

Year-to-date proceeds from financing activities were \$735.3 million in the first nine months of 2013 compared to \$373.5 million in the first nine months of 2012. Net proceeds from short-term borrowings under the Company's commercial paper program were \$1,199.5 million in 2013 compared to \$1,316.3 million in 2012. Cash proceeds from the issuances of common stock were \$138.7 million and \$102.9 million in the first nine months of 2013 and 2012, respectively. Repayments on long-term debt were \$1.7 million and \$1,222.0 million in the first nine months of 2013 and 2012, respectively. Purchases of common stock totaled \$32.6 million and \$217.8 million in 2013 and 2012, respectively. Cash dividends were \$235.0 million in the first nine months of 2013 compared to \$221.3 million in the first nine months of 2012. In January 2013, the Company also elected to prepay the \$350.0 million forward share purchase contract. Refer to Note J, Equity Arrangements, for further discussion. In the first half of 2012, the Company received \$35.8 million from the termination of interest rate swaps, and paid \$56.4 million in relation to the termination of a forward starting interest rate swap. During 2012, the Company received \$729.4 million of net proceeds relating to the issuance of junior subordinated debentures and paid a premium of \$91.0 million relating to the repurchase of three debt instruments with total outstanding principal of \$900.0 million.

Credit Ratings & Liquidity:

The Company maintains strong investment grade credit ratings from the major U.S. rating agencies on its senior unsecured debt (average A-) as well as its short-term commercial paper borrowings. There have been no changes to

any of the ratings during 2013.

Failure to maintain strong investment grade rating levels could adversely affect the Company's cost of funds, liquidity and access to capital markets, but would not have an adverse effect on the Company's ability to access committed credit facilities.

In June 2013, the Company terminated its four year \$1.2 billion committed credit facility with the concurrent execution of a new five year \$1.5 billion committed credit facility (the "Credit Agreement"). Borrowings under the Credit Agreement may include U.S. Dollars up to the \$1.5 billion commitment or in Euro or Pounds Sterling subject to a foreign currency sublimit of \$400.0 million and bear interest at a floating rate dependent upon the denomination of the borrowing. Repayments must be

35

Table of Contents

made on June 27, 2018 or upon an earlier termination date of the Credit Agreement, at the election of the Company. Simultaneously, the Company terminated its \$1.0 billion 364 day committed credit facility with the concurrent execution of a new \$500 million 364 day committed credit facility (the "Facility"). The Facility contains a one year term-out provision and borrowings under the Facility may include U.S. Dollars up to the \$500 million commitment or in Euro or Pounds Sterling subject to a foreign currency sublimit of \$250 million and bear interest at a floating rate dependent upon the denomination of the borrowing. Repayments must be made by June 26, 2014, unless the one year term-out election is made, or upon an earlier termination date of the Facility, at the election of the Company. The Credit Agreement and Facility are designated to be a liquidity back-stop for the Company's \$2.0 billion commercial paper program. As of September 28, 2013, the Company has not drawn on either of these commitments. Concurrently, the guarantees on certain of the Company's outstanding debt obligations were released in accordance with the terms of the indentures governing those obligations. For further information, refer to Note H, Long-Term Debt and Financing Arrangements, and Note T, Parent and Subsidiary Guarantees, in the Notes to (Unaudited) Condensed Consolidated Financial Statements.

In the third quarter of 2011, the Company entered into a forward share purchase contract on its common stock, which obligated the Company to pay \$350.0 million, plus an additional amount related to the forward component of the contract, to the financial institution counterparty not later than August 2013, or earlier at the Company's option, for the 5,581,400 shares purchased. In January 2013, the Company elected to prepay the forward share purchase contract for \$362.7 million, comprised of the \$350.0 million purchase price, plus an additional amount related to the forward component of the contract. In August 2013, the Company physically settled the contract, receiving 5,581,400 shares and \$18.8 million from the financial institution counterparty representing a purchase price adjustment. The reduction of common shares outstanding was recorded at the inception of the forward share purchase contract and factored into the calculation of weighted average shares outstanding.

On July 25, 2012, the Company issued \$750 million of junior subordinated debentures maturing on July 25, 2052 with fixed interest payable quarterly in arrears at a rate of 5.75% per annum. The Company may, at its election, redeem the debentures in whole or in part, at par on or after June 25, 2017. The debentures' subordination, long tenor and interest deferral features provide significant credit protection measures for senior creditors and as a result, the debentures were awarded a 50% equity credit by S&P and Fitch, and a 25% equity credit by Moody's. The net proceeds of \$729 million from the offering was used for general corporate purposes, including the repayment of short term debt and the refinancing of recent and near term debt maturities.

In the third quarter of 2012, the Company repurchased \$900 million of its long term debt via open market tender and exercise of its right under the redemption provision of each notes. The initial funding of the repurchased debt was accomplished by utilizing excess cash on hand and the issuance of Commercial Paper.

Refer to Note H, Long-Term Debt and Financing Arrangements, and Note J, Equity Arrangements, in the Notes to (Unaudited) Condensed Consolidated Financial Statements for further discussion of the Company's financing arrangements.

Cash and cash equivalents totaled \$469 million as of September 28, 2013, comprised of \$57 million in the U.S. and \$412 million in foreign jurisdictions. As of December 29, 2012, cash and cash equivalents totaled \$716 million, comprised of \$99 million in the U.S. and \$617 million in foreign jurisdictions. Concurrent with the Black & Decker merger, the Company made a determination to repatriate certain legacy Black & Decker foreign earnings, on which U.S. income taxes had not previously been provided. As a result of this repatriation decision, the Company has recorded approximately \$418.1 million and \$436.9 million of associated deferred tax liabilities at September 28, 2013 and December 29, 2012, respectively. Current plans and liquidity requirements do not demonstrate a need to repatriate other foreign earnings. Accordingly, all other undistributed foreign earnings of the Company are considered to be permanently reinvested, or will be remitted substantially free of additional tax, consistent with the Company's overall growth strategy internationally, including acquisitions and long-term financial objectives. No provision has been made for taxes that might be payable upon remittance of these undistributed foreign earnings. However, should management determine at a later point to repatriate additional foreign earnings, the Company would be required to accrue and pay

taxes at that time.

OTHER MATTERS

Critical Accounting Estimates: There have been no significant changes in the Company's critical accounting estimates during the third quarter of 2013. Refer to the "Other Matters" section of Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Form 10-K for the year ended December 29, 2012 for a discussion of the Company's critical accounting estimates.

36

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There has been no significant change in the Company's exposure to market risk during the third quarter of 2013. Refer to the "Market Risk" section of Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Form 10-K for the year ended December 29, 2012 for further discussion.

ITEM 4. CONTROLS AND PROCEDURES

Under the supervision and with the participation of management, including the Company's Chairman and Chief Executive Officer and its Senior Vice President and Chief Financial Officer, the Company has, pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), evaluated the effectiveness of the design and operation of its disclosure controls and procedures (as defined under Rule 13a-15(e) of the Exchange Act). Based upon that evaluation, the Company's Chairman and Chief Executive Officer and its Senior Vice President and Chief Financial Officer have concluded that, as of September 28, 2013, the Company's disclosure controls and procedures are effective. There has been no change in the Company's internal control over financial reporting that occurred during the third quarter of 2013 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting. In February 2013, the Company acquired Infastech for \$826 million, net of cash acquired. Management's assessment of, and conclusion on, the effectiveness of internal control over financial reporting excludes the internal controls of Infastech. As part of the ongoing integration activities, the Company will complete an assessment of existing controls and incorporate its controls and procedures into Infastech.

Table of Contents

CAUTIONARY STATEMENT

Under the Private Securities Litigation Reform Act of 1995

Statements in this Quarterly Report on Form 10-Q that are not historical, including but not limited to those regarding the Company's ability to: (i) achieve full year 2013 diluted GAAP EPS of \$3.75 - \$3.95 (\$4.90 - \$5.00 excluding merger and acquisition charges); (ii) generate approximately \$800 million in free cash flow for 2013, excluding merger and acquisition charges and payments; (iii) achieve its 2016/2017 vision; and (iv) achieve long term organic growth of 4% - 6% (collectively, the "Results"); are "forward looking statements" and subject to risk and uncertainty. The Company's ability to deliver the Results as described above is based on current expectations and involves inherent risks and uncertainties, including factors listed below and other factors that could delay, divert, or change any of them, and could cause actual outcomes and results to differ materially from current expectations. In addition to the risks, uncertainties and other factors discussed elsewhere herein, the risks, uncertainties and other factors that could cause or contribute to actual results differing materially from those expressed or implied in the forward looking statements include, without limitation, those set forth under Item 1A Risk Factors of the Company's Annual Report on Form 10-K and any material changes thereto set forth in any subsequent Quarterly Reports on Form 10-Q, or those contained in the Company's other filings with the Securities and Exchange Commission, and those set forth below.

The Company's ability to deliver the Results is dependent, or based, upon: (i) the Company's ability to achieve \$50 million of synergies in 2013 from Black & Decker merger and another \$50 million from the acquisition of Niscayah; (ii) the Company's ability to execute its integration plans and achieve synergies from the Infastech acquisition sufficient to generate \$.20 of EPS accretion in 2013; (iii) the Company's ability to generate organic net sales increases of 3% in 2013; (iv) the Company's ability to generate a modest increase in operating margin vs. the prior year in the CDIY segment and to minimize any decrease in operating margin vs. the prior year in the Security and Industrial segments; (v) the Company's ability to continue to identify and execute upon acquisitions and sales opportunities to increase its CDIY, IAR and Security businesses in the emerging markets while minimizing associated costs; (vi) the Company's ability to achieve a tax rate of approximately 20% in 2013, excluding merger and acquisition charges; (vii) the Company's ability to limit interest expense to approximately \$145 million and other-net to approximately \$250 million in 2013; (viii) the Company's ability to minimize tax liabilities associated with the HHI divestiture; (ix) successful integration of acquisitions completed in 2012 and 2013, and any additional acquisitions completed during the year, as well as integration of existing businesses; (x) the continued acceptance of technologies used in the Company's products and services; (xi) the Company's ability to manage existing Sonitrol franchisee and Mac Tools relationships; (xii) the Company's ability to minimize costs associated with any sale or discontinuance of a business or product line, including any severance, restructuring, legal or other costs; (xiii) the proceeds realized with respect to any business or product line disposals; (xiv) the extent of any asset impairments with respect to any businesses or product lines that are sold or discontinued; (xv) the success of the Company's efforts to manage freight costs, steel and other commodity costs as well as capital expenditures; (xvi) the Company's ability to sustain or increase prices in order to, among other things, offset or mitigate the impact of steel, freight, energy, non-ferrous commodity and other commodity costs and any inflation increases; (xvii) the Company's ability to generate free cash flow and maintain a strong debt to capital ratio; (xviii) the Company's ability to identify and effectively execute productivity improvements and cost reductions, while minimizing any associated restructuring charges; (xix) the Company's ability to obtain favorable settlement of routine tax audits; (xx) the ability of the Company to generate earnings sufficient to realize future income tax benefits during periods when temporary differences become deductible; (xxi) the continued ability of the Company to access credit markets under satisfactory terms; (xxii) the Company's ability to negotiate satisfactory payment terms under which the Company buys and sells goods, services, materials and products; and (xxiii) the Company's ability to successfully develop, market and achieve sales from new products and services.

The Company's ability to deliver the Results is also dependent upon: (i) the success of the Company's marketing and sales efforts, including the ability to develop and market new and innovative products in both existing and new markets; (ii) the ability of the Company to maintain or improve production rates in the Company's manufacturing facilities, respond to significant changes in product demand and fulfill demand for new and existing products; (iii) the

Company's ability to continue improvements in working capital through effective management of accounts receivable and inventory levels; (iv) the ability to continue successfully managing and defending claims and litigation; (v) the success of the Company's efforts to mitigate any cost increases generated by, for example, increases in the cost of energy or significant Chinese Renminbi or other currency appreciation; (vi) the geographic distribution of the Company's earnings; (vii) the commitment to and success of the Stanley Fulfillment System; and (viii) successful implementation with expected results of cost reduction programs.

The Company's ability to achieve the Results will also be affected by external factors. These external factors include: challenging global macroeconomic environment; the continued economic growth of emerging markets, particularly Latin America; pricing pressure and other changes within competitive markets; the continued consolidation of customers particularly in consumer channels; inventory management pressures on the Company's customers; the impact the tightened credit markets may have on the Company or its customers or suppliers; the extent to which the Company has to write off accounts receivable

Table of Contents

or assets or experiences supply chain disruptions in connection with bankruptcy filings by customers or suppliers; increasing competition; changes in laws, regulations and policies that affect the Company, including, but not limited to trade, monetary, tax and fiscal policies and laws; the timing and extent of any inflation or deflation; currency exchange fluctuations; the impact of dollar/foreign currency exchange and interest rates on the competitiveness of products and the Company's debt program; the strength of the U.S. and European economies; the extent to which world-wide markets associated with homebuilding and remodeling stabilize and rebound; the impact of events that cause or may cause disruption in the Company's supply, manufacturing, distribution and sales networks such as war, terrorist activities, and political unrest; and recessionary or expansive trends in the economies of the world in which the Company operates. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date hereof.

PART II — OTHER INFORMATION

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors as disclosed in the Company's Form 10-K for the year ended December 29, 2012 filed with the Securities and Exchange Commission on February 20, 2013 and the Company's Form 10-Q for the quarter ended March 30, 2013 filed with the Securities and Exchange Commission on April 26, 2013.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

The following table provides information about the Company's purchases of equity securities that are registered by the Company pursuant to Section 12 of the Exchange Act during the three months ended September 28, 2013:

	(a) Total Number Of Shares Purchased	Average Price Paid Per Share	Total Number Of Shares Purchased As Part Of A Publicly Announced Program	Maximum Number Of Shares That May Yet Be Purchased Under The Program
2013				
June 30 - August 3	10,474	\$81.87	—	—
August 4 - August 31	—	—	—	—
September 1 - September 28	20,360	85.60	—	—
	30,834	\$84.33	—	—

On July 13, 2012, the Board of Directors approved a new repurchase of up to 20 million shares of the Company's common stock. After the approval, 25.6 million shares of common stock remain authorized for repurchase, of which 5.6 million shares with an average price paid per share of \$61.63 were received in August 2013 in connection with the settlement of the forward share purchase contract (as discussed in Note J, Equity Arrangements).

The shares of common stock in this column were deemed surrendered to the Company by participants in various (a) benefit plans of the Company to satisfy the participants' taxes related to vesting or delivery of time-vesting restricted share units under those plans.

ITEM 6. EXHIBITS

(10.1) Form C of Change in Control Severance Agreement. Several of the Company's Executive Officers, none of whom is a Named Executive Officer, are parties to agreements with the Company in this form.

(11) Statement re-computation of per share earnings (the information required to be presented in this exhibit) appears in Note C to the Company's (Unaudited) Condensed Consolidated Financial Statements set forth in this Quarterly Report on Form 10-Q).

(31)(i)(a) Certification by Chairman and Chief Executive Officer pursuant to Rule 13a-14(a).

(i)(b) Certification by Senior Vice President and Chief Financial Officer pursuant to Rule 13a-14(a).

(32)(i) Certification by Chairman and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(ii) Certification by Senior Vice President and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(101) The following materials from Stanley Black & Decker Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 28, 2013, formatted in XBRL (eXtensible Business Reporting Language); (i) Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 28, 2013 and September 29, 2012 (ii) Condensed Consolidated Balance Sheets at September 28, 2013 and December 29, 2012, (iii) Condensed Consolidated Statements of Cash Flows for the three and nine months ended September 28, 2013 and September 29, 2012, and (iv) Notes to (Unaudited) Condensed Consolidated Financial Statements**.

** Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

STANLEY BLACK & DECKER, INC.

Date: October 28, 2013

By: /s/ DONALD ALLAN, JR.
Donald Allan, Jr.
Senior Vice President and Chief Financial Officer